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FIGURES AND TABLES INDEX 
FIGURE 1: Anatomical origin of breast lesions. 
FIGURE 2: Multistep model of breast cancer evolution. A) Pathways to low grade 
and/or high grade forms of breast cancer based on morphological, 
immunohistochemical and molecular features; connectors drawn with continuous 
lines represent links between morphological entities which are demonstrated by 
morphological and/or molecular data; connectors drawn with discontinuous lines 
represent hypothetical links yet to be demonstrated. B) Pathways stemmed from 
ER status. Note that the two main pathways are defined by the expression of ER 
and ER-regulated genes. In this model, the ER-positive arm encompasses most of 
the precursor lesions and a range of invasive lesions which may progress from low 
to high grade due to the acquisition of genetic instability (GI) and accumulation of 
stochastic genetic events. The ER-negative arm includes ER-negative DCIS and 
invasive tumors; MGA and APH are proposed as non-obligate precursors of these 
lesions. ER and genetic instability bars on either side of the image represent the 
levels of ER expression and genetic instability, respectively. ADH: atypical ductal 
hyperplasia; APH: atypical apocrine hyperplasia; CCH: columnar cell hyperplasia; 
CCL: columnar cell lesion; DCIS: ductal carcinoma in situ; E-cad: E-cadherin; 
FEA: flat epithelial atypia; IDC: invasive ductal carcinoma; ILC: invasive lobular 
carcinoma; LN: lobular neoplasia; MGA: microglandular adenosis; PLCIS: 
pleomorphic lobular carcinoma in situ. 
FIGURE 3: Structural and functional domains of the ETS family of transcription 
factors. Nomenclature and domain organization of the 28 ETS paralogous human 
ETS proteins. The HUGO nomenclature for all ETS proteins and genes are 
highlighted at bold, and the alternative names are also provided. Multiple protein 
products of ETS proteins are synthesized by alternative splicing/start sites, a 
single polypeptide was chosen arbitrarily. Boxes identifying ETS domains are 
represented in orange and the pointed domain (PNT) in green. Other additional 
regions involved in several biological functions were not represented. 
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FIGURE 4: Diagram representing the CGH technique. Tumor and reference 
samples DNA are each labelled with specific fluorochromes, hybridized onto 
normal metaphases and the fluorescence differences evaluated by a specific 
software. 
FIGURE 5: A) Comparative genomic hybridization of a breast carcinoma with 
several copy number changes, showing the most common chromosomal gains 
observed, namely 1q (where ETV3, ELF3 and ELK4 are located), 8q (where MYC 
is located at 8q24), and 17q (where ERBB2 is located at 17q21). Green bars to the 
right and red bars to the left of the chromosome ideograms indicate copy number 
gains and losses, respectively. B) Interphase nuclei with ERBB2 amplification (red; 
control in green). 
FIGURE 6: A) CGH profile of chromosome 1 showing two discrete copy number 
gains including 1q21~q23 (ETV3 locus) and 1q32 (ELF3 and ELK4 loci) together 
with a large 1p terminal deletion. B) CGH profile of chromosome 1 showing two 
discrete copy number gains including 1q21~q23 (ETV3 locus) and 1q32 (ELF3 
and ELK4 loci) together with a small interstitial 1p deletion. C) Interphase FISH 
analysis demonstrating copy number gain of ETV3 (green) and ELF3 (red). D) 
Interphase FISH analysis of another breast carcinoma demonstrating copy number 
gain of ETV3 (green) and ELK4 (red). 
FIGURE 7: Box-plot graph showing ELF3 expression according to the presence or 
absence of 1q32 copy number gain (Mann Whitney test). 
FIGURE 8: Non-parametric correlation between ELK4 and MYC mRNA expression 
(Spearman test). 
FIGURE 9: A) Comparison of disease-specific survival for 1q copy number status in 
luminal A breast carcinomas, as compared to the basal molecular subtype 
showing the worst prognosis. B) Comparison of disease-specific survival for ELF3 
expression above and below the mean in luminal A breast carcinomas, as 
compared to the basal molecular subtype showing the worst prognosis. The 
differences were not statistically significant. 
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TABLE 1: Histological breast cancer classification. 
TABLE 2: Breast cancer grading: Elston-Ellis system. 
TABLE 3: TNM classification of carcinomas of the breast. 
TABLE 4: Staging of breast cancer based on TNM classification. 
TABLE 5: Clinicopathological characterization of 141 breast cancer patients. 
TABLE 6: Group of ETS genes and the possible ETS target genes selected for 
gene expression analysis. 
TABLE 7: Description of CGH results, immunohistochemistry evaluation for ER, 
PgR and cytokeratin markers and molecular classification of 141 breast 
carcinomas. 
























































The following abbreviations, listed in alphabetical order, were used throughout the 
text: 
  more or equal to 
<  less than 
>  more than 
µL  microliter 
18S rRNA RNA, 18S ribosomal 
3T3-L1 mice (Mus musculus) embryonic fibroblastic cell line  
ABC reagent avidin-biotin complex reagent 
ADH  atypical ductal hyperplasia 
AEG  Crisp 1 alias 
AKT  v-akt murine thymoma viral oncogene homolog 1 
ALK  anaplastic lymphoma receptor tyrosine kinase 
APH  atypical apocrine hyperplasia 
BAC  bacteria artificial chromosome 
bp   base pair 
BSA  bovine serum albumin 
CCH  columnar cell hyperplasia 
CCL  columnar cell lesion 
CDC-2 cyclin-dependent kinase 1 
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c-Fos  FBJ murine osteosarcoma viral oncogene homolog 
CGH  comparative genomic hybridization 
CHiP  chromatin immunoprecipitation 
CI  confidence interval 
CISH  chromagenic in situ hybridization 
CK(s)  cytokeratin(s) 
cm  centimeter 
C-MYB MYB alias 
C-MYC MYC alias 
CREB-1 cAMP responsive element binding protein 1 
CREM-1 cAMP responsive element modulator 
CRISP1 cysteine-rich secretory protein 1 
CRISP2 cysteine-rich secretory protein 2 
CRISP3 cysteine-rich secretory protein 3 
DAB  3,3'-diaminobenzidine 
DAPI  4'-6-diamidino-2-phenylindole dihydrochloride 
DBD  DNA binding domain 
DCIS  ductal carcinoma in situ  
DDX20 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 
DEAD box DEAD (Asp-Glu-Ala-Asp) box polypeptide 
DNA  deoxyribonucleic acid 
Abbreviations 
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E-cad  E-cadherin 
EDTA  ethyleno dyamino tetracetic acid 
EHF  ets homologous factor 
ELF3  E74-like factor 3 (ets domain transcription factor, epithelial-specific) 
ELF5  E74-like factor 5 
ELK4  ELK4, ETS-domain protein (SRF accessory protein 1) 
ER  estrogen receptor 
ERBB2 codifying gene of Her2/neu 
ERG  v-ets erythroblastosis virus E26 oncogene homolog (avian) 
ERK2  MAPK1 alias 
ESE  epithelial specific ETS 
ETS  E26 transformation-specific family 
ETS1  v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 
ETS2  v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 
ETV1  ets variant 1 
ETV3  ets variant 3 
ETV4  ets variant 4 
ETV5  ets variant 5 
ETV6  ets variant 6 
FEA  flat epithelial atypia 
FISH  fluorescent in situ hybridization 
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FLI1  friend leukemia virus integration 1 
h  hour(s) 
H&E  hematoxylin and eosin 
Her2/neu Her2 protein 
HPRT1 hypoxanthine phosphoribosyltransferase 1 
IDC  invasive ductal carcinoma 
IDC-NST invasive ductal carcinoma not otherwise specified 
IgePal octylphenyl-polyethylene glycol 
ILC  invasive lobular carcinoma 
ISCN  International System for Chromosome Nomenclature 
ITC  isolated tumor cells 
kDa  kilodaltons 
Ki67  monoclonal antibody specific to the protein MKI67 
LN  lobular neoplasia 
M  molar 
MAPK mitogen-activated protein kinase 1 (official symbol MAPK1) 
MAST  microtubule-associated serine-threonine kinase 
MCF-12A human (Homo sapiens) epithelial mammary gland immortalized cell 
line 
mg  milligram 
MGA  microglandular adenosis 
min  minute(s) 
Abbreviations 
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mL  milliliter 
mm  millimeter 
mM  millimolar 
MYB  v-myb myeloblastosis viral oncogene homolog (avian) 
MYC  v-myc myelocytomatosis viral oncogene homolog (avian) 
NaCl  sodium chloride 
NaCSN sodium isothiocyanate 
NFIB  nuclear factor i/b 
NF-kB nuclear factor-kappa B 
ng  nanogram 
NTRK3 neurotrophic tyrosine kinase, receptor, type 3 
NUP214 nucleoporin 214kDa 
ºC  degree Celsius 
PAK1  p21 protein (Cdc42/Rac)-activated kinase 1 
PBS  phosphate buffered saline 
PgR  progesterone receptor 
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
alpha (official symbol PIK3CA) 
PLCIS pleomorphic lobular carcinoma in situ 
PNT  pointed domain 
PTEN  phosphatase and tensin homolog 
qRT-PCR quantitative real time PCR 
Abbreviations 
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RAS v-Ki-RAS2 Kirsten rat sarcoma viral oncogene homolog (official 
symbol KRAS) 
RPS6KB1 ribosomal protein S6 kinase, 70kda, polypeptide 1 
s  second(s) 
SAR  serine and aspartic acid domain 
SDS  sodium dodecyl sulphate 
SLC45A3 solute carrier family 45, member 3 
SRF  serum response factor 
SSC  saline-sodium citrate buffer 
TCF   ternary complex factor 
TGF-β transforming growth factor beta 1 (official symbol TGFB1) 
TGF-βRII transforming growth factor beta receptor II (official symbol TGFBR2) 
TLDA  Taq®Man Low-Density Arrays 
TLDU  terminal lobular ductal unit 
TMPRSS2 transmembrane protease, serine 2 
TWEEN 20 polyethylene glycol sorbitan monolaurate 
VMP1  vacuole membrane protein 1 
w/v  weight/volume 



















































Several ETS transcription factors are involved in the pathogenesis of human 
cancers by different mechanisms. As gene copy number gain/amplification is an 
alternative mechanism of oncogenic activation and 1q gain is the most common 
copy number change in breast carcinoma, we investigated how that genomic 
change impacts in the expression of the three 1q ETS family members ETV3, 
ELK4 and ELF3. We have first evaluated 141 breast carcinomas for genome-wide 
copy number changes by chromosomal CGH, and showed that 1q21 and 1q32 
were the two chromosome bands with most frequent genomic copy number gains. 
Second, we confirmed by FISH with locus-specific BAC clones that cases showing 
1q gain/amplification by CGH showed copy number increase of the ETS genes 
ETV3 (located in 1q21~23), ELF3 and ELK4 (both in 1q32). Third, gene 
expression levels of the three 1q ETS genes, as well as their potential targets 
MYC and CRISP3, were evaluated by quantitative real-time PCR. We here show 
for the first time that the most common genomic copy number gains in breast 
cancer, 1q21 and 1q32, are associated with overexpression of the ETS 
transcription factors ETV3 and ELF3 (but not ELK4) at these loci irrespective of 
molecular subtypes. Among the three 1q ETS genes, ELF3 has a relevant role in 
breast carcinogenesis and is also the most likely target of the 1q copy number 
increase. The basal-like molecular subtype presented the worst prognosis 
regarding disease-specific survival, but no additional prognostic value was found 
for 1q copy number status or ELF3 expression. Additionally, we show that there is 
a correlation between the expression of the oncogene MYC, irrespectively of copy 
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number gain at its locus in 8q24, and the expression of both the transcriptional 



















































Os factores de transcrição ETS estão envolvidos na carcinogénese via diferentes 
mecanismos. O ganho/amplificação de número de cópias génicas é um dos 
mecanismos de activação oncogénica. No cancro da mama, o ganho de 1q é a 
alteração de número de cópias mais comum. Baseando-nos nestes factos, 
postulámos qual seria o impacto das alterações genómicas na expressão de três 
genes membros da família dos ETS (ELF3, ETV3 e ELK4), cujos loci estão em 1q. 
Avaliámos por CGH cromossómico as possíveis alterações do número de cópias 
genómicas em 141 carcinomas da mama e demonstrámos que as bandas 
cromossómicas 1q21 e 1q32 apresentavam a frequência mais elevada de ganhos 
de cópias cromossómicas. De seguida, confirmámos por FISH com sondas locus-
específicas obtidas por clones de BACs, que nos casos que apresentavam 
ganhos/amplificações de 1q por CGH também se verificava o aumento de número 
de cópias de ETV3 (loci 1q21~23), ELF3 e ELK4 (ambos localizados em 1q32). 
Avaliámos os níveis de expressão génica por PCR quantitativo em tempo real dos 
três genes ETS localizados em 1q, bem como potenciais genes alvo, 
nomeadamente os genes MYC e CRISP3. Assim, neste trabalho reportámos pela 
primeira vez que os ganhos de cópias genómicos mais comuns no cancro da 
mama, 1q21 e 1q32, estão associados com a sobre-expressão dos factores de 
transcrição ETV3 e ELF3 (o mesmo não se verificando para o ELK4), 
independentemente do subtipo molecular. De entre os três genes ETS localizados 
em 1q, o ELF3 tem um papel relevante na carcinogénese mamária e é o alvo 
mais provável do aumento de número de cópias de 1q. O subtipo molecular basal-
like apresentou o pior prognóstico analisando a sobrevivência específica de 
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doença, mas não se verificou valor de prognóstico adicional no que concerne ao 
número de cópias de 1q ou à expressão de ELF3. Adicionalmente, demonstrou-se 
que existe uma correlação entre a expressão do oncogene MYC, 
independentemente do ganho do número de cópias no locus 8q24, e a expressão 



















































Breast cancer is the most common malignancy among western women and the 
second cause of cancer death (1). About 40 000 women die each year in the 
United States of metastatic breast cancer and the mortality rate is higher in 
developing countries, making this disease a public health problem (1, 2). The 
disease incidence is increasing due to, among other factors, the implementation of 
screening programs and population ageing (3). The decline of the mortality rate 
during the last two decades from 30% to 20%, despite the aggressiveness of the 
conventional therapies and the early detection of patients at initial stages of the 
disease, is far from the desirable (4). Metastatic breast cancer is still clinically 
incurable (4). In Portugal, breast cancer is the malignancy with the highest 
incidence and the second cause of death by cancer among women (5). 
1. BREAST DISEASES 
1.1. BREAST TISSUE AND ASSOCIATED PATHOLOGIES 
To better understand breast pathologies, the contextualization of normal breast 
tissue anatomy is a requirement. Breasts are composed of specialized epithelium 
and stroma that may give rise to both benign and malignant lesions (6, 7). 
The epithelial component consists of a series of branching ducts which bond the 
structural and functional units of the breast, i.e., the lobules to the nipple (Figure 
1).  
The stroma, which comprises almost all breast volume in the nonlactational state, 
is constituted of variable amounts of adipose and fibrous connective tissues (6, 7). 
Successive branching of the large ducts ultimately leads to the terminal lobular 
duct unit (TLDU). Each ductal system often occupies more than one quadrant of 




FIGURE 1: Anatomical origin of breast lesions [adapted from (7, 8)]. 
Throughout women’s reproductive life time, during menstrual cycles, pregnancy, 
breastfeeding and menopause, the breast tissue is exposed to several boosts of 
hormonal driven cycles, which result in variations of the tissue composition of the 
organ (4, 5). These proliferation and differentiation cell cycles are DNA error prone 
and increase the risk of tumor development. 
The clinical presentation of breast pathologies more frequently reported by women 
are mastalgia or mastodynia, nipple discharges and palpable mass or lumpiness 
(7). 
1.2. BREAST CANCER 
1.2.1. RISK AND PROTECTIVE FACTORS 
The breast is a hormonal dependent tissue and, consequently, among the risk 
factors that have been associated with breast cancer, gender is the most 
important, as reflected by male breast cancer representing only 1% of the new 
breast cancer cases diagnosed (9, 10). Age is also associated with augmented 
risk of developing breast cancer: the incidence of the disease rises in elderly 
women and the peak occurs at the age of 70-80 years, being 61 years the average 
age at diagnosis for Caucasian women and 56 and 46 years for Hispanic and 
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African-American women, respectively (1, 7, 9). The reproductive maturation and 
all the events associated with hormonal cycles are also risk factors, namely (7): 
 Age at menarche and menopause: women that reach menarche younger than 
11 years old have 20% increased risk comparing to women in whom it occurs 
latter than 14 years; late menopause also increases the risk of breast cancer 
development (11); 
 Age at first live birth and breast feeding: the first full term pregnancy at ages 
younger than 20 years reduce breast cancer risk in 20%, comparing to women 
having the first child after the age of 35 years. Regarding breast feeding, women 
who breastfeed for longer periods have a decreased risk of developing the 
disease; 
 Estrogen exposure: hormonal replacement therapy increases the risk 1.2 to 
1.7 fold, and adding progesterone increases the risk even further. Oral 
contraception is not consensually associated with breast cancer risk reduction, but 
is associated with diminished risk of ovarian and endometrial cancers. 
Another group of risk factors is the personal and the family history of breast 
pathologies. Breast cancer risk increases with the number of affected first degree 
relatives and a history of biopsies for atypical hyperplasias, especially when 
detected, increases the risk of invasive carcinomas. After a primary breast cancer 
event, the risk of developing a contralateral tumor raises 1% per year (7). 
Other risk factors are (7): 
 Race/ethnicity: Caucasian women present the highest risk of developing 
breast cancer; 
 Breast density: anatomically dense breasts have higher risk of developing 
neoplastic processes due to breast physiology and also to the obstacles to 
mammographic screening; 
 Radiation exposure: due to treatments, accidents or labor activities, radiation 
exposure increases the probability of developing breast cancer; 
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 Geographic influence, diet, obesity and exercise: breast cancer incidence in 
the United States and in Europe is four times higher than in other countries. 
Healthy life style habits are not consensually associated with diminished breast 
cancer risk, but are clearly coupled to less morbidity; 
 Smoking habits: tobacco is not clearly associated with breast cancer, although 
it is an obvious risk factor for health status in general. 
1.2.2. DIAGNOSIS 
The majority of breast cancer patients presents clinical signals and 
symptomatology, such as lumps, nipple discharges, areola alterations, or even 
skin deformations. These common findings in symptomatic patients may be 
accompanied by pain, but an increasing proportion of breast cancers are being 
diagnosed in asymptomatic phases due to mammographic screening (3). 
Traditionally, breast abnormalities should be evaluated by triple assessment, 
including clinical, imaging (mammographic and ultrasound) and 
anatomopathological evaluation (by aspirative cytology or biopsy). Based on the 
preoperative clinical diagnosis estimated by the integration of the histological 
type/grade of the tumor (Tables 1 and 2), clinical TNM staging (Table 3) and 
estrogen receptor (ER), progesterone receptor (PgR) and Her2-neu status, 
assessed when primary systemic therapy is planned, the treatment scheme can 




TABLE 1: Histological breast cancer classification [adapted from (12)]. 
HISTOLOGICAL TYPE ICD-O* 
Epithelial tumors  
Invasive ductal carcinoma, not otherwise specified 8500/3 
Mixed type carcinoma  
Pleomorphic carcinoma 8022/3 
Carcinoma with osteoclastic giant cells 8035/3 
Carcinoma with choriocarcinomatous features  
Carcinoma with melanotic features  
Invasive lobular carcinoma 8520/3 
Tubular carcinoma 8211/3 
Invasive cribiform carcinoma 8201/3 
Medullary carcinoma 8510/3 
Mucinous carcinoma and other tumors with abundant mucin  
Mucinous carcinoma 8480/3 
Cystoadenocarcinoma and columnar cell mucinous carcinoma 8480/3 
Signet ring carcinoma 8490/3 
Neuroendocrine tumors  
Solid neuroendocrine carcinoma  
Atypical carcinoid tumor 8249/3 
Small cell/oat cell carcinoma 8041/3 
Large cell neuroendocrine carcinoma 8013/3 
Invasive papilary carcinoma 8503/3 
Invasive micropapilary carcinoma 8507/3 
Apocrine carcinoma 8401/3 
Metaplastic carcinoma 8575/3 
Pure epithelial metaplastic carcinoma 8575/3 
Squamous cell carcinoma 8070/3 
Adenocarcinoma with spindle cell metaplasia 8572/3 
Adenosqamous carcinoma 8560/3 
Mucoepidermoid carcinoma 8430/3 
Mixed epithelial/mesenchymal metaplastic carcinoma 8575/3 
Lipid-rich carcinoma 8314/3 
Secretory carcinoma 8502/3 
Oncocytic carcinoma 8290/3 
Adenoid cystic carcinoma 8200/3 
Acinic cell carcinoma 8550/3 
Glycogen-rich cell carcinoma 8315/3 
Sebaceous carcinoma 8410/3 
Inflammatory carcinoma 8530/3 
Lobular neoplasia  
Lobular carcinoma in situ 8520/2 
Intraductal proliferative lesions  
Usual hyperplasia  
Flat epitheilial atypia  
Atypical ductal hyperplasia  
Ductal carcinoma in situ 8500/2 
Microinvasive carcinoma  
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HISTOLOGICAL TYPE ICD-O* 
Epithelial tumors (cont.)  
Intraductal papillary neoplasms  
Central papilloma 8503/0 
Peripheral papilloma 8503/0 
Atypical papilloma  
Intraductal papillary carcinoma 8503/2 
Intracystic papillary carcinoma 8504/2 
Benign epithelial proliferations  
Adenosis including variants  
Sclerosing adenosis  
Apocrine adenosis  
Blunt duct adenosis  
Microglandular adenosis  
Adenomyoepithelial adenosis  
Radial scar/complex sclerosing lesion  
Adenomas  
Tubular adenoma 8211/0 
Lactating adenoma 8204/0 
Apocrina adenoma 8401/0 
Pleomorphic adenoma 8940/0 
Ductal adenoma 8503/0 
  
Myoepithelial lesions  
Myoepethiliosis  
Adenomyoepithelial adenosis  
Adenomyoepithelioma 8982/0 
Malignant myoepthelioma 8982/3 
  




Pseudoangiomatous stromal hyperplasia  
Myofibroblastoma 8825/0 
Fibromatosis (aggressive) 8821/1 
Inflammatory myofibroblastic tumor 8825/1 
Lipoma 8850/0 
Angiolipoma 8861/0 











HISTOLOGICAL TYPE ICD-O* 
Fibroepithelial tumors  
Fibroadenoma 9010/0 




Periductal stromal sarcoma, low grade 9020/3 
Mammary hamartoma  
  
Tumors of the nipple  
Nipple adenoma 8506/0 
Syringomatous adenomas 8407/0 
Paget disease of the nipple 8540/3 
  
Malignant lymphoma  
Difuse large B-cell lymphoma 9680/3 
Burkitt lymphoma 9687/3 
Extranodal marginal-zone B cell lymphoma of MALT cell type 9699/3 
Follicular lymphoma 9690/3 
  
Metastatic tumors  
  




In situ 8500/2 
Legend: *Morphology code of the International Classification of Diseases for Oncology (ICD-O) and the 
Systematized Nomenclature of Medicine (12); /0 for benign tumors, /1 for borderline or uncertain behavior, /2 
for in situ carcinomas and grade 3 intraepithelial neoplasias, and /3 for malignant tumors [extracted from (12)].  
TABLE 2: Breast cancer grading: Elston-Ellis system [adapted from (12)]. 
FEATURE SCORE 
Tubule and gland formation  
Majority of tumors (>75%) 1 
Moderate degree (10-75%) 2 
Little or none (<10%) 3 
Nuclear pleomorphism  
Small, regular uniform cells 1 
Moderate increase in size and variability 2 
Marked variation 3 
Mitotic counts  





TABLE 3: TNM classification of carcinomas of the breast [adapted from (12)]. 
TNM CLINICAL CLASSIFICATION 
T-Primary Tumor 
Tx Primary tumor cannot be accessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget)
1 
Paget disease of the nipple with no tumor 
T1 Tumor 2cm or less in greatest dimension 
T1mic Microinvasion 0.1cm or less in greatest dimension
2
 
T1a More than 0.1cm but not more than 0.5cm in greatest dimension 
T1b More than 0.5cm but not more than 1cm in greatest dimension 
T1c More than 1cm but not more than 2cm in greatest dimension 
T2 Tumor more than 2cm but not more than 5cm in greatest dimension 
T3 Tumor more than 5cm in greatest dimension 
T4 
Tumor of any size with direct extension to chest wall or skin only as described in 
T4a to T4d 
T4a Extension to chest wall 
T4b 
Edema (including peau d’orange), or ulceration of the skin of the breast, or 
satellite skin nodules confined to the same breast 





N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed (e.g. previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis in movable ipsilateral axillary lymph node(s) 
N2 
Metastasis in fixed ipsilateral axillary lymph node(s) or in clinically apparent
4
 
ipsilateral internal mammary lymph node(s) in the absence of clinically evident 
axillary lymph node metastasis 
N2a Metastasis in axillary lymph node(s) fixed to one another or to other structures 
N2b 
Metastasis only in clinically apparent
4
 internal mammary lymph node(s) and in 
the absence of clinically evident axillary lymph node metastasis 
N3 
Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary 
lymph node involvement; or in clinically apparent
4
 ipsilateral internal mammary 
lymph node(s) in the presence of clinically evident axillary lymph node 
metastasis; or metastasis in ipsilateral supraclavicular lymph node(s) with or 
without axillary or internal mammary lymph node involvement 
N3a Metastasis in infraclavicular lymph node(s) 
N3b Metastasis in internal mammary and axillary lymph nodes 
N3c Metastasis in supraclavicular lymph node(s) 
  
M – Distant Metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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TNM CLINICAL CLASSIFICATION 
pTNM Pathological Classification 
pT The pathological classification requires the examination of the primary carcinoma with no gross tumor at 
the margins of resection. A case can be classified pT if there is only microscopic tumor in a margin. The pT 
categories correspond to the T categories
1
 
pN Regional Lymph Nodes 
pNX 
Regional lymph nodes cannot be assessed (not removed for study or previously 
removed) 




Micrometastasis (larger than 0.2mm, but none larger than 2mm in greatest 
dimension 
pN1 
Metastasis in 1-3 ipsilateral axillary lymph node(s), and/or in internal mammary 
nodes with microscopic metastasis detected by sentinel lymph node dissection 




Metastasis in 1-3 axillary lymph node(s), including at least one larger than 2mm 
in greatest dimension 
pN1b 
Internal mammary lymph nodes with microscopic metastasis detected by sentinel 
lymph node dissection but not clinically apparent 
pN1c 
Metastasis in 1-3 axillary lymph node(s) and internal mammary lymph nodes with 
microscopic metastasis detected by sentinel lymph node dissection but not 
clinically apparent 
pN2 
Metastasis in 4-9 ipsilateral axillary lymph nodes, or in clinically apparent
7
 
ipsilateral internal mammary lymph node(s) in the absence of axillary lymph node 
metastasis 
pN2a 
Metastasis in 4-9 axillary lymph nodes, including at least one that is larger than 
2mm 
pN2b 
Metastasis in clinically apparent internal mammary lymph node(s), in the 
absence of axillary lymph node metastasis 
pN3 
Metastasis in 10 or more ipsilateral axillary lymph nodes; or in infraclavicular 
lymph nodes; or in clinically apparent ipsilateral internal mammary lymph nodes 
in the presence of one or more positive axillary lymph nodes; or in more than 3 
axillary lymph nodes with clinically negative, microscopic metastasis in internal 
mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes 
pN3a 
Metastasis in 10 or more axillary lymph nodes (at least one larger than 2mm) or 
metastasis in infraclavicular lymph nodes 
pN3b 
Metastasis in clinically apparent internal mammary lymph node(s) in the 
presence of one or more positive axillary lymph node(s); or metastasis in more 
than 3 axillary lymph nodes and in internal mammary lymph nodes with 
microscopic metastasis detected by sentinel lymph node dissection but not 
clinically apparent 
pN3c Metastasis in supraclavicular lymph node(s) 
pM – Distant Metastasis  
The pM categories correspond to the M categories 
Legend: 
1
Paget disease associated with a tumor is classified according to the size of the tumor. 
2
Microinvasion is the extension of cancer cells beyond the basement membrane into the adjacent tissues with 
no focus more than 0.1cm in greatest dimension. When there are multiple foci of microinvasion, the size of 
only the largest focus is used to classify the microinvasion (the sum of all individual foci should not be used). 
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TABLE 3 – Legend (cont): The presence of multiple foci of microinvasion should be noted, as it is with multiple 
larger invasive carcinomas. 
3
Inflammatory carcinoma of the breast is characterized by diffuse, brawny 
induration of the skin with an erysipeloid edge, usually with no underlying mass. If the skin biopsy is negative 
and there is no localized measurable primary cancer, the T category is pTX when pathologically staging a 
clinical inflammatory carcinoma (T4d). Dimpling of the skin, nipple retraction, or other skin changes, except 
those in T4b and T4d, may occur in T1, T2, or T3 without affecting the classification. 
4
Clinically apparent = 
detected by clinical examination or by imaging studies (excluding lymphoscintigraphy). 
5
When classifying pT 
the tumor size is a measurement of the invasive component. If there is a large in situ component (e.g. 4cm) 
and a small invasive component (e.g. 0.5cm), the tumor is coded pT1a. Cases with only isolated tumor cells 
(ITC) in regional lymph nodes are classified as pN0. ITC are single tumor cells or small clusters of cells, not 
more than 0.2mm in greatest dimension, that are usually detected by immunohistochemistry or molecular 
methods but which may be verified on H&E stains. ITCs do not typically show evidence of metastatic activity 
(e.g., proliferation or stromal reaction). 
6
Not clinically apparent = not detected by clinical examination or by 
imaging studies (excluding lymphoscintigraphy). 
7
Clinically apparent = detected by clinical examination or by 
imaging studies (excluding lymphoscintigraphy) or grossly visible pathologically [extracted from (12)]. 
1.2.3. BREAST CANCER CLASSIFICATION 
Breast cancer can be classified according to several features, namely tissue 
histology, grade, stage and phenotypical/genomic markers. 
1.2.3.1. BREAST CANCER HISTOLOGICAL CLASSIFICATION  
Breast carcinomas can be divided into in situ and invasive lesions. The carcinoma 
in situ is a neoplastic proliferation limited to the ducts and lobules by the basement 
membrane, whereas invasive carcinoma has already penetrated through the 
basement membrane into the stroma, and the cells have the potential to invade 
into the vasculature and thereby reach the regional lymph nodes and distant sites 
(7). 
The initial taxonomy of breast lesions reflected the assumption that breast cancers 
would arise from distinct microanatomical structures of the normal breast, hence 
the terminology of duct and lobular carcinomas. Latter, Wellings et al (13-17), 
called into question this assumption as they proved that the vast majority of these 
lesions originate from the TLDUs regardless of histological type. Hence, the terms 
duct and lobular carcinoma do not entail the histogenesis within the mammary 
ductal system, rather these entities are defined by their discrete architectural 
patterns, cytological features and immunohistochemical profiles (18). This was a 
paradigm shift at the time and culminated in the perception that the origin of the 
invasive lesions results in several histogenetic models of breast cancer 
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progression. Additionally molecular data now available suggest that in situ lesions 
are at least as heterogeneous as their invasive counterparts (19). Nevertheless, 
nowadays this terminology still persists. 
Besides the cell of origin, the diversity of clinical behavior and biological features 
that breast cancer presents highlighted the need to categorize the disease into 
meaningful clusters, in order to easily plan the therapeutic schemes and improve 
the prognosis. During the last decades the committed efforts for establishing a 
working flow chart model for breast cancer taxonomy have been put forward, but 
they were not as successful as expected. Breast cancers are often composed of 
areas that harbor distinct morphological patterns (18), which is a drawback to an 
easy and expeditious taxonomical approach. Several breast cancer histological 
classifications are currently in use (18), but the latest World Health Organization 
(WHO) classification provides a valuable operational flow through model for breast 
cancer taxonomy and recognizes the existence of 18 types of breast cancer (Table 
1) (12, 18). 
Invasive ductal carcinomas not otherwise specified (IDC-NST) account for the 
large majority (50-80%) of breast carcinomas. This group comprises 
adenocarcinomas that fail to exhibit enough characteristics to warrant their 
classification into one of the special types (18). The last edition of WHO 
classification of breast cancer recognizes the existence of at least 17 histological 
special types, namely the lobular and medullar invasive carcinomas (12, 18) 
(Table 1). 
1.2.3.2. BREAST CANCER GRADING 
Histological grade in parallel with histological type are the two most important 
tumor intrinsic features that can be determined by histopathological analysis of a 
breast cancer specimen. Tumor grade is an assessment of the degree of 
differentiation (that is, tubule formation and nuclear pleomorphism) and 
proliferative activity (the mitotic index) of a tumor and indicates the tumor 
aggressiveness (18). Due to interobserver disagreement, the need of easily 
classifying systems urged. With the introduction of the Nottingham histological 
grading system based on Elston-Ellis grading system (Table 2) and the 
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standardization of criteria through external quality assurance schemes, this pitfall 
has been avoided. In fact, recent studies have demonstrated a moderate to good 
correlation between molecular tests and histological grade, whether the tests are 
performed by local pathologists or at a central laboratory (18). 
Nowadays, histological grade has been incorporated into multiple algorithms, such 
as the Nottingham Prognostic Index and Adjuvant! Online, to determine the 
prognosis of the breast cancer patients. Furthermore, tumor grade correlates with 
prognostic molecular subtypes identified by microarray analysis, and microarray-
based genomic signatures for histological grading have been devised (18). 
1.2.4. MOLECULAR SUBTYPES 
With the advent of high-throughput methodologies, valuable tools became 
available to breast cancer researchers uncover the molecular pathways 
underpinning carcinogenesis and metastatic proclivity. The establishment of 
molecular portraits could thus trigger tailored therapy implementation stemmed on 
pathological signatures, associated with prognosis and response to therapies. The 
seminal works performed by Sorlie and Perou (20), the Stanford group, based on 
hierarchical gene cluster analysis, led to the development of a molecular 
classification of breast cancers that comprised the subtypes luminal (A and B), 
basal and normal-like, and Her-2. Later, it was attested the prognostic significance 
of this classification (18, 21-24). The interobserver subjectivity observed with the 
classic histological classification based on the several flow through working 
models described above hampered its universal acceptance among the 
pathologists. Gene expression profiling could be the solution to a global 
classification of breast cancer, perhaps becoming the gold standard technique, but 
besides economical issues, the appliance of this technique was precluded by the 
facts that called into question the validity of this taxonomy (18). Therefore, for risk 
estimation and choice of adjuvant systemic therapies for patients with operable 
breast cancers, information on ER, PgR, and Her2-neu proteins expressions is still 
routinely utilized worldwide (24). The intrinsic subtypes can also be defined more 
simply at the protein expression level by immunohistochemistry for ER, PgR, 
Her2-neu, and myoepithelial/basal markers, eg, cytokeratins (CKs) 5/6, CK17, and 
CK14 (24, 25).  
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In luminal A and B subtypes the estrogen receptor is upregulated. The luminal A 
tumors represent approximately 40% of breast carcinomas (7, 26). The majority is 
well or moderately differentiated and most occur in postmenopausal women. 
These cancers are generally slow growing and respond well to hormonal therapy. 
Conversely, only a small number respond to standard chemotherapy. The gene 
signature is dominated by dozens of ER regulated genes (27). Luminal B group 
comprises 15-20% of breast carcinomas and also expresses ER, but generally 
present higher grade, higher proliferative rate, and often overexpress Her2-neu 
(26, 27). They are sometimes defined as triple positive cancers and compose the 
major group of ER-positive cancers that are more likely to be associated with 
lymph node metastases and that may respond to chemotherapy (27). The normal-
like tumors representativeness is low and it is not yet clear whether or not this is a 
specific tumor expression pattern (28). This small group of usually well 
differentiated ER-positive, Her2-neu negative cancers, is characterized by the 
similarity of their gene expression pattern to normal tissue (27). The basal-like 
group, which represents 15-20% of breast cancers (26), is notable for the absence 
of ER, PgR and Her2-neu proteins and the expression of typical markers of 
myoepithelial cells (basal keratins, P-cadherin, p63 or laminin), progenitor cells, or 
putative stem cells (CKs 5 and 6). They have special genetic and epidemiological 
features, and generally present high grade and proliferation rate (27). They are 
associated with an aggressive course, frequent visceral and brain metastases, and 
poor prognosis. However, approximately 40% will have a pathologic complete 
response to chemotherapy; cure may be possible in this chemosensitive subgroup 
(27). Finally, Her2-neu positive breast cancer, which comprises 10-15% of breast 
cancers (27), are ER-negative carcinomas that overexpress the Her2-neu protein. 
In over 90% of Her2-neu positive cancers, overexpression is due to amplification 
of the segment of DNA on 17q21 that includes ERBB2 (alias: Her2) and varying 
numbers of neighbor genes. This amplicon dominates the gene signature of this 
group. These cancers are usually poorly differentiated, have a high proliferation 
rate, are associated with a high frequency of brain metastases and have an 




1.3. BREAST CANCER TREATMENT 
Surgery is the usual first line treatment, being breast conservation surgery the 
ideal surgical approach. The decision depends upon the initial assessment of 
tumor size and extent, and the presence of axillary lymph node metastases, which 
is the most powerful prognostic determinant in primary operable breast cancer (3, 
29). 
After surgery each patient should have a plan for adjuvant therapies. The adjuvant 
treatments have been shown to reduce the risk of recurrence and to improve 
overall survival (29). Postoperative pathological assessment of the surgical 
specimen should be made according to the pathological TNM staging system 
(Table 4), and also taking into account several biological tumor characteristics, 
such as histological type and grade (Tables 1 and 2) and immunohistochemical 
evaluation of ER, PgR, Ki67 and Her2-neu. ERBB2 (alias Her2) gene amplification 
status should be determined by in situ hybridization techniques as chromagenic in 
situ hybridization (CISH) or fluorescent in situ hybridization (FISH) if 
immunohistochemistry results are doubtful (3, 30, 31). 
TABLE 4: Staging of breast cancer based on TNM classification [adapted from (12)]. 
STAGE GROUPING T N M 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1, N2 M0 
Stage IIIB T4 N0, N1, N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
The integration of the clinical parameters into scores (e.g. Nottingham Prognostic 
Index) that allow to accurately estimate the probability of recurrence and/or death 
are useful clinical tools to stratify patients and establish the best adjuvant 
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therapeutic scheme, being radiotherapy the most common adjuvant treatment 
option (29). Conventional systemic therapy, if the patient’s benefit surpasses the 
risks and side effects, is also offered. According to tumor ER and Her2-neu status, 
endocrine or targeted therapy, respectively, may also be recommended (3). 
These combined therapy approaches have been successful, in view of the almost 
steady state of breast cancer mortality during the past three decades. Although 
implementation of individualized therapy is now possible, about 60% of all patients 
with early-stage breast cancer still receive adjuvant chemotherapy, of which only a 
small proportion, 2-15% of patients, will ultimately derive benefits, all being 
subjected to the risk of toxic side effects (27). Furthermore, this treatment 
approach is not cost effective. The hunt for prognostic markers that accurately 
predict the risk of developing breast cancer or the progression of the disease is 
therefore far away from being completed.  
2. PATHWAYS TO BREAST CANCER 
Despite the therapeutic arsenal available, breast cancer is still a public health 
problem. The cases diagnosed as breast cancer are described as a complex and 
heterogeneous collection of pathologies of the same anatomical site, originated 
from the same anatomical structure (i.e., TLDU) but encompassing different 
pathobiological entities. They are characterized by different risk factors, 
histological features, and a scope of clinical behaviors and response to treatment, 
and ultimately disease related morbidity and mortality. These features cannot be 
determined by anatomical prognostic factors (i.e., tumor size or nodal status), but 
rather by intrinsic molecular characteristics of the tumors that can be probed with 
molecular methods (27).  
The study of cancer genetics has had an enormous impact in our understanding of 
the development and progression of breast neoplasias. The high-throughput 
methodologies applied over the last few years to the analysis of malignant and 
precursor lesions of the breast were extremely important to bring some light into 
the pathways of breast carcinogenesis. They provide strong circumstantial 
evidence that the multitude of pathological phenotypes and diverse behavior are 
molecularly underpinned by complex patterns of genetic and epigenetic 
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alterations, which deregulate the control of some genes, and concomitantly the 
cellular pathways associated with them, destabilizing vital cell processes (32). 
Breast carcinogenic pathways remain an incompletely solved conundrum, partly 
due to the diversity of prognosis, even among patients with similar clinical stages. 
2.1. STEP BY STEP TOWARDS BREAST CANCER 
The least understood step of breast carcinogenesis is the transition of carcinoma 
in situ to invasive carcinoma. Contrarily to other tumors, such as colon cancer, it 
has been difficult to understand the molecular events underlying the development 
of a precursor breast lesion into an overtly malignant phenotype, namely due to 
methodological obstacles, like the scarceness of samples of precursor lesions and 
the difficulty to translate in vitro to in vivo models (19). 
Additionally, the identification of specific genetic tumor markers has been difficult. 
If we look carefully to normal breast tissue function, we encounter intricate and 
exceedingly complicated pathways that depend on the interplay between luminal, 
myoepithelial and stromal cells. The same molecular events that allow the normal 
formation of new ductal branch points and lobules during pregnancy and puberty, 
namely abrogation of the basement membrane, increased proliferation, escape of 
growth inhibition, angiogenesis, and invasion of the stroma, may be recapitulated 
during carcinogenesis (7). Remodeling of the breast, which involves inflammatory 
and wound healing like tissue reactions, could explain the transient increase in 
breast cancers during and shortly after pregnancy, since such changes could 
facilitate the transition of carcinoma in situ to invasive cancer (7). 
Several models of breast carcinogenesis have been proposed. Wiechamnn et al 
(33) proposed two models: the multistep model or the “theory of linear 
progression” and the “theory of parallel disease”. The former model supports that 
tumor progression follows a linear pattern and thus invasive breast cancer 
develops after breast disease proceeds through sequential stages, from 
premalignant hyperplastic breast lesion with and without atypia (atypical ductal 
hyperplasia, atypical lobular hyperplasia and usual ductal hyperplasia), to 
carcinoma in situ (ductal or lobular) and to invasive carcinoma. This model has 
been supported by molecular and clinical evidence, but the behavior of non 
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invasive lesions is inconsistent. Fifty percent of ductal carcinoma in situ progress 
to invasive breast cancer, but the range of time of progression from non malignant 
lesion to an overt malignant phenotype is highly variable (33). In the second 
model, low grade non invasive lesions are committed to progress to low grade 
invasive counterparts, and the same correspondence is established between non 
invasive and invasive high grade lesions. The idea that these two models are 
mutually exclusive may represent an oversimplification (33).  
Breast cancer is a genetic disease in which the major risk factors for its initiation 
and proliferation are genetic and hormonal, as mentioned above. The sporadic 
forms are specially influenced by exposition to hormones. In accordance with this 
evidence, the majority of breast cancers are ER positive and occur in 
postmenopausal women. Probably these carcinomas arise from ER-expressing 
luminal cells, which is supported by the phenotype of some precursor lesions, 
such as atypical hyperplasias, that are more similar to this type of cells. ER-
negative carcinomas may arise from ER-negative myoepithelial cells. This would 
explain why many proteins found in myoepithelial cells are shared by the triple-
negative (the standard evaluated markers are unexpressed) or basal-like cancers 
(7). 
From studies addressing genotypic-phenotypic correlations has become apparent 
that estrogen receptor positive and negative breast cancers are two distinct 
pathological entities (19). Within ER-positive breast cancer, histological grade and 
proliferation are strongly associated with the extent, complexity and type of genetic 
aberrations (19). Lopez-Garcia et al (19) proposed two working models based on 
histological grade, immunohistochemistry and molecular features of breast cancer, 





FIGURE 2: Multistep model of breast cancer evolution. A) Pathways to low grade and/or high grade 
forms of breast cancer based on morphological, immunohistochemical and molecular features; 
connectors drawn with continuous lines represent links between morphological entities which are 
demonstrated by morphological and/or molecular data; connectors drawn with discontinuous lines 
represent hypothetical links yet to be demonstrated. B) Pathways stemmed from ER status. Note 
that the two main pathways are defined by the expression of ER and ER-regulated genes. In this 
model, the ER-positive arm encompasses most of the precursor lesions and a range of invasive 
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FIGURE 2 (CONT): lesions which may progress from low to high grade due to the acquisition of 
genetic instability (GI) and accumulation of stochastic genetic events. The ER-negative arm 
includes ER-negative DCIS and invasive tumors; MGA and APH are proposed as non-obligate 
precursors of these lesions. ER and genetic instability bars on either side of the image represent 
the levels of ER expression and genetic instability, respectively. ADH: atypical ductal hyperplasia; 
APH: atypical apocrine hyperplasia; CCH: columnar cell hyperplasia; CCL: columnar cell lesion; 
DCIS: ductal carcinoma in situ; E-cad: E-cadherin; FEA: flat epithelial atypia; IDC: invasive ductal 
carcinoma; ILC: invasive lobular carcinoma; LN: lobular neoplasia; MGA: microglandular adenosis; 
PLCIS: pleomorphic lobular carcinoma in situ [extracted from (19)]. 
2.2. MOLECULAR BASIS OF BREAST CANCER 
All cancers carry somatic mutations in their genomes. A subset, known as driver 
mutations, confer clonal selective advantage on cancer cells and are causally 
implicated in oncogenesis, and the remainder are considered passenger mutations 
(34). 
When compared to normal cells, neoplastic cells present the so-called “hallmarks 
of cancer”. These features print to cells special capabilities necessary for cancer 
initiation and progression, namely the limitless capability of mitosis, self-sufficient 
growth promoting signals, to induce angiogenesis, the abilities to evade inhibitory 
growth control and invade surrounding and distant tissues, resistance to 
apoptosis, reprogramming cellular metabolism and to avoid the immune system. 
After developing all these competences, the cell is prepared to turn into a 
neoplastic cell. 
2.2.1. ONCOGENES AND TUMOR SUPPRESSOR GENES 
Breast cancer develops as a consequence of the accumulation of carcinogenic 
mutations in the genomes of the evolving neoplastic cells. These mutations range 
from point mutations and copy number changes affecting only a few nucleotides 
up to gain or loss of whole chromosomes, or large fractions of chromosomes at a 
greatly increased rate compared with normal cells. The resulting effects of these 
aberrations are the activation of cancer promoting genes (oncogenes) and/or the 
inactivation of genes that protect the cells from malignant transformation (tumor 
suppressor genes). Another important class of genes, the caretakers, maintain 
cells’ genomic stability. When these genes are inactivated, cancer may occur, as a 
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cell loses its ability to maintain the normal mutation rate and therefore the 
likelihood of arising carcinogenic mutations increases.  
Oncogenes overexpression, such as ERBB2 (35, 36) and MYC (37), and loss of 
tumor suppressor genes, like TP53 (38) or PTEN (39), are proposed to underlie 
breast cancer initiation and progression. Several mechanisms are involved in gene 
activation/inactivation and may contribute to breast carcinogenesis (32, 40, 41).  
2.2.2. EPIGENETIC ALTERATIONS 
Epigenetic alterations have been described as a carcinogenic mechanism in many 
cancers, including in breast tumorigenesis (42). Cancer genomes as a whole are 
hypomethylated, but the hypermethylation of CpG islands in the neighborhood of 
promoters leads to gene silencing, which is a common mechanism for inactivation 
of tumor suppressor genes. 
2.2.3. ANEUPLOIDY AND CHROMOSOMAL ALTERATIONS  
Aneuploidy is defined as the gain and/or loss of whole chromosomes and is almost 
ubiquitously found in neoplastic lesions. It is frequently caused by chromosomal 
instability defined as the inability of cells to properly divide the chromosomal set 
into the daughter cells (43). Aneuploidy may contribute to carcinogenesis by the 
inactivation of tumor suppressor genes, by physical elimination of a gene or its 
regulatory regions, or by the activation of oncogenes, due to a dosage effect (43). 
This phenomenon can be related to a gene in particular, but it is usually 
associated to the disequilibrium of a gene set.  
There are several reports in the literature using conventional cytogenetics and 
comparative genomic hybridization (CGH) showing recurrent chromosomal 
alterations in breast cancer specimens, namely gain of 1q, 8q, 16p, 17q, and 20q 
and loss of 16q and 17p (44-47). However, the candidate genes localized in these 
regions have not yet been identified. 
Genomic amplifications are the selective increase in copies of DNA. They can 
involve a single gene encompassing a few kilobases or multiple genes, 
neighboring or located in distant genomic locations. These events have classically 
been related to cytogenetic features, such as double-minutes, self replicating 
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extra-chromosomal elements, or homogeneously staining regions, where multiple 
copies of a single or several genomic regions are incorporated into a chromosome 
(48). On the other hand, homozigous deletions that commonly occur in neoplastic 
cells are thought to primarily inactivate tumor suppressor genes. Nevertheless, the 
deletion mechanism can also result in a fusion gene, such as the TMPRSS2–ERG 
in prostate cancer (49). This kind of events may be associated with the presence 
of fragile sites. The occurrence of fragile sites across the genome can also be 
associated with recurrent homozigous deletions in cancer cells (50). 
Another mechanism for oncogene activation is translocation, which is the most 
common mechanism of origin of fusion genes, whose activity is different from the 
ones that originated them. Any badly repaired event that generated double strand 
DNA breaks can be responsible for the origin of a fusion transcript. The discovery 
of translocations involving the ETS-family members in prostate cancer, as well as 
genes like ALK in lung cancer (51), suggests that fusion genes may play a more 
prominent role in epithelial carcinogenesis than previously thought. Fusion genes 
have rarely been described in breast cancer cell lines and tumor samples, but rare 
breast cancer subtypes are characterized by recurrent fusion transcripts, namely 
the secretory breast carcinoma with the ETV6-NTRK3 transcript and the adenoid 
cystic carcinoma of the breast with the fusion transcript MYB-NFIB (52). Recently, 
rare but recurrent rearrangements of the NOTCH and MAST family genes (e.g. 
NOTCH1-NUP214) (53), as well as the recurrent RPS6KB1-VMP1 fusion (54), 
were also described in breast cancer.  
2.2.4. ETS GENES 
The E26 transformation-specific (ETS) family of genes is restricted to metazoans 
and thus represents an evolutionarily recent class of transcription factors (55, 56). 
These genes regulate a spectrum of normal biological activities, namely cell 
differentiation, development, homeostasis, proliferation, and apoptosis. It is one of 
the largest transcription factor families, consisting of 28 ETS genes in humans (55, 
56). The ETS family is defined by the ETS domain, a highly conserved DNA-
binding domain (DBD), which is a purine-rich core sequence localized within the 




FIGURE 3: Structural and functional domains of the ETS family of transcription factors. 
Nomenclature and domain organization of the 28 ETS paralogous human ETS proteins [grouped 
according (57)]. The HUGO nomenclature for all ETS proteins and genes are highlighted at bold, 
and the alternative names are also provided. Multiple protein products of ETS proteins are 
synthesized by alternative splicing/start sites, a single polypeptide was chosen arbitrarily. Boxes 
Identifying ETS domains are represented in orange and the pointed domain (PNT) in green. Other 
additional regions involved in several biological functions were not represented [adapted from (57)].  
The ETS genes also play important roles in oncogenesis. Deregulated expression 
or genetic alterations of ETS genes are thought to represent a significant role in 
the development of human neoplasias (56). Chromosomal translocations involving 
ETS genes have been reported in hematological and soft tissue malignancies and 
result in an inappropriate expression level or expression as fusion proteins (56). 
The role of this family of genes in epithelial cancers (carcinomas) was less 
established until recently, when ERG, ETV1, ETV4, ETV5 and FLI1 were shown to 
be fused with TMPRSS2, or other 5’ fusion partners, in a significant proportion of 
prostate carcinomas (58-60). These fusion oncogenes are thought to increase 
ETS expression in response to androgen, leading to prostate epithelial cell 
transformation (59). 
Secretory breast cancers, a very unusual histological breast cancer type 
(represents less than 1% of infiltrating breast carcinomas) (61), presents a 
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recurrent chromosomal translocation, t(12;15)(p13;q25) (62). This cytogenetic 
finding had previously been described in congenital fibrosarcoma, congenital 
mesoblastic nephroma, and acute myeloid leukemia (63-65). The translocation 
generates a gene fusion encoding the dimerization domain of the transcription 
factor ETV6 and the tyrosine kynase domain of the NTRK3 (62). The protein 
ETV6-NTRK3 functions as a potent chimeric protein tyrosine kinase, with in vivo 
and in vitro transforming activity, which leads to constitutive activation of the RAS-
MAPK mitogenic pathway and the PI3K-AKT pathway (66). This unique ability may 
be crucial for its carcinogenic capability. Additionally, transcriptome studies have 
also indicated that many of the molecular changes associated with breast cancer 
are mediated by altered function of transcription factors, namely ETS genes (67-
69). 
ETS genes are also involved in healthy breast tissue proliferation and 
differentiation. Studies performed with mice suggest relevant roles for ETV4, ETV5 





















































The main goals of this work were: 
1) To identify the pattern of genome alterations in a large series of breast 
carcinomas; 
2) To characterize the pattern of gene expression alterations of the ETS family of 
transcription factors; 
3) To determine the role of genomic copy number gains and amplifications on 
overexpression of the ETS proteins; 
4) To uncover target genes affected by altered expression of ETS transcription 
factors; 
5)  To establish the prognostic value of gene expression alterations of ETS 
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MATERIAL AND METHODS 
1. PATIENTS AND TUMOR SPECIMENS 
The tumor samples used in this study were collected from breast cancer patients 
treated at the Portuguese Oncology Institute-Porto, who underwent potentially 
curative resection between 1999 and 2001. After pathological examination tumors 
were snapped frozen in liquid nitrogen and subsequently stored at -80ºC until the 
molecular analysis were performed. A total of 141 specimens were evaluated 
during this study. We selected the first consecutive cases, with follow-up data of 
10 years, of this series of fresh-frozen breast carcinoma samples. The 
clinicopathological characteristics were obtained for all patients and their clinical 
course revised by two independent oncologists. This data is summarized in Table 
5. 
Paired frozen and paraffin-embedded samples were re-evaluated to assure the 
representativeness of cancer cells (>75% of tumor cells). Fifteen 15µm thick tissue 
sections of frozen tissue were used for DNA and RNA isolations. Sections of 
paraffin embedded tissue were used as described below to analyze ER, PgR and 
CKs 5/6 and 14 by immunohistochemistry, as well as copy number changes of 
ERBB2 and particular ETS genes by FISH. 
2. IMMUNOHISTOCHEMICAL CHARACTERIZATION 
The breast carcinomas were retrospectively re-evaluated independently by two 
pathologists for morphological and immunohistochemistry characterization. This 
step ensured that all breast cancer specimens were reclassified using the 
standard methods in use nowadays. Commercially available antibodies were used 
for ER (Clone 6F11; Novocastra, Newcastle, UK) and PgR (Clone 16; Novocastra, 
Newcastle, UK), as well as for CKs 5/6 (Clones: D5 & 16B4; Cell Marque; Rocklin, 
CA, USA) and 14 (Clone SP53; Cell Marque; Rocklin, CA, USA).  
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TABLE 5: Clinicopathological characterization of 141 breast cancer patientsa. 
CLINICOPATHOLOGICAL CHARACTERISTICS 
Age at diagnosis (mean±SE) 59.3 ±1.2 





























Carcinoma in situ*  
Without 32.6% 
Not extensive 37.6% 
Extensive 28.4% 
Family history of cancer* 34.0% 






Adjuvant radiotherapy* 70.9% 
Follow up status*  
Alive disease free 63.8% 
Alive with disease 5.7% 
Dead disease free 21.3% 
Dead with disease 7.8% 
Legend: 
a
All patients were diagnosed before anti-ERBB2 agents became available. 
b
Based on stage grouping 
defined by World Health Organization (12). *Data not available for all patients. 
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The tissue slides were deparaffinized by rinsing with xylol and rehydrated by 
passing through graded alcohols (absolute ethanol, 90%, 80%, 70%, 50%). 
Antigen retrieval was performed with citratre buffer. Endogenous peroxidase 
activity was blocked by incubating the slides for 20min in 0.3% H2O2 (aq). After 
washing the slides in water and PBS/0.05% Tween 20 solution, they were 
incubated with normal serum (Vectastain Universal Elite ABC Kit, Vector 
Laboratories, Burlingame, CA, USA) 1/100 in PBS-Bovine Serum Albumine (BSA) 
1%, at room temperature for 20min in a humid chamber. After incubation, the 
respective primary antibodies were added at an optimal dilution for each antibody 
in PBS-BSA 1% solution, and the slides were incubated overnight at 4°C in a 
humid chamber. The slides were then rinsed in PBS/0.05% Tween 20 solution and 
bound antibody was detected by applying biotinylated secondary antibody and 
ABC reagent from the Vectastain Universal Elite ABC kit (Vector Laboratories, 
Burlingame, CA, USA). The slides were washed in PBS and developed with a 
peroxidase substrate solution [0.05% 3,3’-diaminobenzidine tetrahydrochloride 
(DAB 3,3’-Diaminobenzidine, Sigma-Aldrich, Steinheim, Germany) and 0.01% 
H2O2 in PBS] during 7min. Counterstaining was then performed with hematoxylin 
(Harris Modified Hematoxylin Stain, Fisher Scientific, Fair Lawn, NJ, USA) for 30s 
and washed for 10min in H2O. Slides were mounted with Entellan (Merck KGaA, 
Darmstadt, Germany). For each antibody appropriate positive and negative breast 
cancer controls were used. The control samples used were breast cancer tumor 
specimens analyzed by immunohistochemistry and revaluated by FISH. Sections 
were scored as negative when <10% and as positive when 10% of stained cells 
were present.  
3. ERBB2 GENE CHARACTERIZATION 
ERBB2 status was evaluated by FISH using a dual color commercial probe 
(Poseidon, Kreatech Diagnostics, Amsterdam, The Netherlands), targeting the 
chromosome 17 centromere and the ERBB2 gene. The centromeric probe is 
directly labeled with PlatinumBright495 and produce green signals; the ERBB2 
gene probe is labeled with PlatinumBright550 and present red signals The ERBB2 
status classification followed international consensus guidelines (31). The cases 
not analyzable by FISH were scored according to the CGH results, as CGH and 
FISH present an 82% concordance regarding ERBB2 status (71). One hundred 
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and twenty six cases were classified by FISH and 15 cases were classified 
according to the CGH results. From each of the paraffin-embedded samples, four-
micron thick sections of a representative tissue block were cut onto SuperFrost 
Plus Adhesion slides (Menzel-Glaser, Braunschweig, Germany). Slides were 
deparaffinized in two series of xylol followed by two series of ethanol, rinsed in 
2xSSC, and placed in a solution of NaSCN 1M at 80ºC. Tissues were then 
digested with pepsin, after which slides were rinsed in 2xSSC and dehydrated in 
an ethanol series. The probes were applied onto each sample and slides were 
placed in a Hybrite denaturation/hybridization system and co-denatured. 
Hybridization took place overnight, followed by post-hybridization washes in 
2xSSC/0.5% Igepal and 2xSSC/0.1% Igepal, after which slides were 
counterstained with DAPI. Fluorescent images corresponding to each 
fluorochrome and DAPI were sequentially captured with a Cohu 4900 CCD 
camera, using an automated filter wheel coupled to a Zeiss Axioplan fluorescence 
microscope and a CytoVision system. Only intact, non-overlapping nuclei were 
scored.  
4. COMPARATIVE GENOMIC HYBRIDIZATION 
Our initial goal was to evaluate the global pattern of chromosomal alterations in 
this series of the breast carcinomas. The chosen methodology was CGH, a 
technique that provides an overview of the changes in DNA copy number across 
the whole genome (Figure 4).  
 
FIGURE 4: Diagram representing the CGH technique. Tumor and reference samples DNA are each 
labelled with specific fluorochromes, hybridized onto normal metaphases and the fluorescence 
differences evaluated by a specific software. 
Tumor samples were digested with proteinase K (20mg/mL) in a lyses buffer [NaCl 
75mM, 25mM EDTA (pH 8) and SDS (10%)], at 55ºC until complete digestion. 
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DNA was extracted with phenol-chlorophorm (pH 8), precipitated with isopropanol 
and ammonium acetate, reprecipitated in ethanol and eluted in water. DNA quality 
was evaluated by agarose gel (0.8%; w/v) electrophoresis and the quantity and 
purity were measured in Nanodrop (ND-1000 Spectrophotometer, Wilmington, 
USA). 
The CGH procedure described by Kallioniemi et al [12] was performed with 
modifications previously described in Teixeira et al [8] and Ribeiro et al [13]. 
Briefly, test DNA (tumor sample) and reference DNA (genomic DNA extracted 
from blood lymphocytes from healthy donors) were differentially labeled with green 
and red fluorescent dyes, respectively, by nick translation using fluorochrome-
conjugated nucleotides, resulting in fragment lengths between 300–2000bp. Test 
and reference DNA were mixed in a 1:1 proportion with unlabeled human Cot-1 
DNA (Invitrogen, Life Technologies, Carlstad CA, USA), ethanol precipitated, 
dried, and dissolved in hybridization buffer. DNA probes and commercially 
available normal metaphase chromosomes, prepared from normal lymphocyte 
cultures, were denatured following by co-hybridization (2-3 days in humidified 
chamber at 37ºC). After a series of washes, the slides were mounted in an 
antifade solution with DAPI. Using a Cytovision system with software version 3.9 
(Applied Imaging, Santa Clara, CA, USA), chromosomes were identified based on 
their inverted DAPI appearance and the relative hybridization signal intensity 
determined along each chromosome. Data obtained from ten cells were combined 
to generate average ratio profiles with 99% confidence intervals (CI) for each 
chromosome. Ten cells of each of ten normal versus normal hybridizations were 
used to establish the normal ratio profile with 99% CI [14]. Copy number gains and 
losses were scored whenever the test and the reference 99% CI did not overlap. 
Amplifications were scored whenever the 99% CI of the fluorescence ratio was 
above 1.5 in part of a given chromosome arm. The description of the CGH copy 
number changes followed the guidelines suggested by the ISCN [15].  
5. COPY NUMBER EVALUATION OF THE ETV3, ELF3 AND ELK4 GENES 
Based on the results obtained after CGH, we evaluated the copy number of the 
ETS genes on 1q. Locus-specific probes derived from bacterial artificial 
chromosomes (BACs) were selected according to physical and genetic mapping 
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data on chromosomes reported in the Human Genome Browser at the University 
of California, Santa Cruz website (http://genome.ucsc.edu/). BAC clones targeting 
ETV3 (CTD3076J23A), ELF3 (RP11465N4B and CTD2545E14B) and ELK4 
(CTD2218H7B) were selected to cover each of the three genes and obtained from 
the BACPAC Resources Center (Oakland, California, USA). Adequate mapping 
and probe specificity of all BAC clones was confirmed by hybridization onto normal 
human metaphases. DNA was extracted using the Plasmid DNA Purification Kit 
(MACHEREY-NAGEL GmbH & Co. KG, Duren, Germany) and amplified using the 
GenomiPhi V2 DNA Amplification Kit (WGA kit, GE, Healthcare, Buckinghamshire, 
UK) according to the manufacturer’s instructions. After a 5min pre-treatment at 
90ºC, BAC DNA was labeled with SpectrumGreen or SpectrumRed (Abbott 
Laboratories, IL, USA) conjugated nucleotides in nick translation reactions using 
the same protocol as described above for CGH. Seven hundred ng of each 
labeled BAC probe was then mixed with 30μg unlabeled Cot-1 DNA (Invitrogen, 
Life Technologies), ethanol precipitated, dried, and dissolved in hybridization 
buffer (Abbott Laboratories, IL, USA). We selected cases for FISH validation 
according to the CGH findings, including 10 cases without 1q alterations, 10 with 
1q amplifications and 10 with 1q gain. The FISH technique was performed as 
described above. 
6. GENE EXPRESSION 
Gene expression of a set of ETS genes was analyzed by quantitative real-time 
PCR (qRT-PCR) (Table 6). Our choice was based on previous published results 
(69) and on the CGH results. We also choose a panel of potential ETS target 
genes, namely CRISP3 and MYC, which have been described as possible ETS 
target genes in hormone dependent tumors such as breast and prostate cancers 
(37, 60, 72-76).  
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TABLE 6: Group of ETS genes and the possible ETS target genes selected for gene expression 
analysis. 




ELF3 1q32.2 Hs00231786_m1* 74 
ELK4 1q32 Hs01111811_m1* 61 
ETV5 3q28 Hs00231790_m1* 70 
ETV1 7p21.3 Hs00951941_m1* 110 
ETS1 11q23.3 Hs00901425_m1* 67 
FLI1 11q24.1~q24.3 Hs00956711_m1* 157 
ETV4 17q21 Hs00385910_m1* 95 
ETS2 21q22.2 Hs00232009_m1* 93 
ERG 21q22.3 Hs01554635_m1* 104 
CRISP3 6p12.3 Hs00195988_m1* 111 
MYC 8q24.21 Hs00153408_m1* 107 
HPRT1
b 








Legend: *”_m”: indicates an assay whose probe spans an exon junction and will not detect genomic DNA. 
a
“_s”: indicates an assay whose probes and primers are designed within a single exon and, hence, will detect 
genomic DNA. 
b
The two normalizing genes used. 
c
Multiple loci in distinct chromosomes. 
d
According to Applied 
Biosystems, Life Technologies based on assay re-evaluation in August 2010 with NCBI Entrez Gene 
annotations, this assay may detect transcript(s) from off target gene. Our work was complete before this date. 
Total RNA was extracted from frozen breast tumor samples using Trizol® Reagent 
(Invitrogen, Life Technologies) and PureLink®RNA Mini Kit (Invitrogen, Life 
Technologies) as per the manufacturer’s instructions. All RNA samples were 
digested with TURBO DNAse (Ambion, Applied Biosystems, Life Technologies, 
Rockville, MD), according to the manufacturer’s instruction, to improve the purity of 
the RNA and avoid genomic DNA contamination in subsequent RT-PCR. The 
quality of the RNA was checked by electrophoresis on 1% (w/v) agarose gel and 
the quantity and the purity ratio were evaluated in a Nanodrop 1000 (ND-1000 
Spectrophotometer). Samples showing intact 28S and 18S rRNA bands were 
selected for the analysis. 
In order to improve the amount of total RNA and obtain cDNA, we used 
Transplex®, an Whole Transcriptome Amplification (WTA) method (Sigma-Aldrich, 
Saint Louis, Missouri, USA) (77). Briefly, for the library preparation, to 5–300ng of 
total RNA, we added 2.5µL WTA Library Synthesis Buffer and 2.5µL WTA Library 
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Stabilization Solution and completed with Nuclease-free water for a total volume of 
24µL. After incubation at 70°C for 5min, the reaction was immediately cooled on 
ice and then we added 1µL of WTA Library Synthesis Enzyme and incubated in 
thermal cycler (24C for 15min; 42C for 2h; 95C for 5min). The reaction was 
immediately chilled on ice. Then we proceeded to library amplification: after 
preparing a WTA Amplification Mix (300µL Nuclease-free water; 37.5µL WTA 
Amplification Master Mix; 7.5µL dNTP Mix; 12.5 units of antibody inactivated hot-
start Taq DNA Polymerase), we added 70µL of this mixture to each 5µL aliquot of 
the library, and incubated in thermal cycler using the following parameters: 95°C 
for 3min; 94°C for 20s, and 65°C for 5min (20 cycles). Then we purified the cDNA 
with a commercial kit (Quiagen, West Sussex, UK). 
Quantitative PCR reactions were performed on a ABI Prism 7900 HT sequence 
detection system, using Taq®Man Low-Density Array (TLDA) (Applied 
Biosystems, Life Technologies). The primers and probes of each assay targeting 
the elected ETS genes and their potential target genes and the two normalizing 
housekeeping genes (18S and HPRT) were preloaded and dried onto designated 
duplicate wells. In the literature there is no consensus on which is the best 
reference gene for gene expression analyzes of breast carcinomas (78, 79), so we 
decided to use the median gene expression results after normalization with each 
reference gene to minimize sample variability and to increase the accuracy and 
resolution of gene expression normalization. 
7. STATISTICAL ANALYSIS 
The non-parametric Mann-Whitney or Kruskal Wallis tests were used to compare 
RNA expression levels of ETS genes in different sample groups. To assess 
associations of continuous variables, the Spearman non-parametric correlation 
test (rs) was used. Kaplan Meyer curves and log rank tests were used to evaluate 
differences between disease survival and breast cancer molecular subtypes. 
Correlations between 1q gain and breast cancer molecular subtypes were 
evaluated using the Chi square test. A p-value smaller than 0.05 was considered 
statistically significant. Statistical analyses were performed using the Statistical 



















































1. ERBB2 STATUS AND IMMUNOHISTOCHEMISTRY  
Ninety six cases were considered negative (68.1%) and 45 positive (31.9%) for 
ERBB2 amplification (Figure 5).  
 
FIGURE 5: A) Comparative genomic hybridization of a breast carcinoma with several copy number 
changes, showing the most common chromosomal gains observed, namely 1q (where ETV3, ELF3 
and ELK4 are located), 8q (where MYC is located at 8q24), and 17q (where ERBB2 is located at 
17q12). Green bars to the right and red bars to the left of the chromosome ideograms indicate copy 
number gains and losses, respectively. B) Interphase nuclei with ERBB2 amplification (red; control 
in green). 
Regarding the hormone receptor status, 70.2% (99 cases) and 58.9% (83 cases) 
were considered ER and PgR positive, respectively. Thirty cases (22.9%) were 
hormonal receptors negative (both ER and PgR), 81 cases (61.8%) were positive 
for both hormonal receptors, and 20 cases (15.2%) were positive for one of them 
(18 ER positive/PgR negative; two RE negative/PgR positive). Regarding 
cytokeratin expression, 32 cases (25.6%) were considered positive, 93 (66%) 
were negative, and 16 were not analyzable for CKs 5/6 expression, with the 
findings for cytokeratin 14 being 15 (10.6%), 113 (80.1%), and 13, respectively 
(Table 7).  
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TABLE 7: Description of CGH results, immunohistochemistry evaluation for ER, PgR and 
cytokeratin markers and molecular classification of 141 breast carcinomas. 

































1 rev ish enh(2p14p16,4q28,8q11q24,11p12p15,17q21q25,20q11q13), amp(8q22q24) + + - + - Luminal A 
2 
rev ish enh(1p32p35,1q12q24,2p23p24,3q12q29,5p13p15,6p12p24,6q23q27,8p11p12,8q13q21,8q22q24, 
9p13p23,10q21q23,11q14q24,12p11p13,12q14q15,16p12p13,18p11,18q21q22,20p11p13,20q11,21q22), 
dim(4q31q35,5q12q35,8p21p22,10p11p15,10q24q26,13q14q33,19p13,22q11q13),amp(3q21q25,8q24,10q22) 
+ + - - - Luminal A 
3 rev ish enh(1q31q42,3q21,3q27q28,16p12p13,17q23q25),dim(3p21,8p23,11q22q24,16q12q24) + + - - - Luminal A 
4 rev ish enh(17q23q25),dim(16q11q24,17p11p13) + - - + - Luminal A 
5 rev ish enh(8p22,8q11q24,16p12p13),dim(1p36,16q11q24) + + - + - Luminal A 
6 
rev ish enh(1p13,8p11p21,10p12p14,11p11p15,17q23q24,19q13,20q11q13),dim(1p31,3p13p21, 
6q13q22,9p12p24,9q12q34,10q11q26,11q23q25,14q32,17p11p13),amp(20q12q13) 
+ + - - ? Luminal A 
7 rev ish enh(8p12,8q11q24),dim(6q21q27,16q11q24,17p12p13) - + - - - Luminal A 
8 




- - - - + Basal-like 
9 rev ish enh(17q21q24),dim(17p12p13) + + + - - Luminal B 
10 rev ish enh(1q12q42) + + - ? - Luminal A 
11 No alterations + - - - - Luminal A 
12 rev ish enh(1q21q43,8p23q24,11q13),dim(9q12q34,11q14q25,16q12q24,17p12p13) + + - - - Luminal A 
13 rev ish enh(8p21q24,16p11p13),dim(8p21p23,16q12q24),amp(8p11q24) + + - - - Luminal A 
14 rev ish enh(11q13q21,17q21q24,20q11q13),dim(4p13p16,8p21p23,17p12p13,18p11,18q11q21) + - + - - Luminal B 
15 rev ish enh(1q12q43),dim(13q12q34,16q12q24,17p11p13) + + + - - Luminal B 
16 
rev ish enh(1p31p35,1q21q43,2q34q37,8q11q24,9p12q13,9q34,12q13q15,16p11p13,20q11q13,22q11q13), 
dim(4q25q34,7q33q36,8p12p23,15q22,16q12q24,18q21q22,19q13,21q21),amp(1p32,8q21q24,20q12) 
+ + + - - Luminal B 
17 rev ish enh(8q12q24,10q22q23,15q22q25) + + - - + Luminal A 
18 rev ish enh(1q12q43),dim(7q22q32,16q11q24) + + - + - Luminal A 
19 rev ish enh(11p12p15,11q13q14) + - + - - Luminal B 
20 rev ish enh(1q12q42,16p11p12),dim(16q12q24,22q13) + + - - - Luminal A 
21 rev ish enh(8p11p21,8p23,8q24,19q13),amp(8p12p21,19q13) + + - - - Luminal A 
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rev ish enh(7,8p21q11,14q24q32,18q11q23,22q13),dim(2p22p23,2q21q31,2q34q37,6q13q22,8p21p23, 
11q21q25,13q12q34,17p11p13,17q21),amp(8p12p21,18q12q22) 
+ + + - - Luminal B 
23 
rev ish enh(1q21q43,6p12p25,7p13p21,7q11,8q24,9q21q34,10p11p15,10q21q22,10q26,12p12p13,12q13q24, 
14q13q32,16p11p13,20),dim(1p21p36,7q33q36,8p21p23,9p22p24,10q24,13q13q34,16q12q24,17p12p13, 
17q11),amp(1q31q43) 
+ + - - - Luminal A 
24 




- - - ? + Basal-like 
25 
rev ish enh(1p21p31,2q11,11p15,14q23q24,17q11q25,20q11q13),dim(1p36,3p14p21,11q22q24,18q21q22), 
amp(1p31,17q12,17q23q24,20q12q13) 
+ - + - - Luminal B 
26 
rev ish enh(1q21q43,11q13,12q13q14,16p11p13,17q12q21,19q13,20), 
dim(6p21q27,9p13p21,11q23q25,15q11q25,16q12q24,21q22,22q13),amp(1q21q42) 
+ + - - - Luminal A 
27 No alterations  - - - - - Basal-like* 
28 
rev ish enh(1q22q42,2q22q37,3p12p13,3q12,6p22,6q21q27,7p21p22,7q31q36,8q12q24,9p22p24,10p13p15, 
11p12p15,12p13,12q21q24,13q31q34,16p13,16q12q23,17q25,18q12,20q11q13),dim(1p36,4p13p16,4q31q35, 
5q22q23,5q33,8p21p23,13q13,17q21,18p11) 
- - + + + ERBB2 positive 
29 No alterations + + - - - Luminal A 
30 
rev ish enh(6p21p24,8q11q24,11p11p15,12p11p13,12q12q24,16p11p13,21q21q22), 
dim(11q22q25,16q12q24,22q11q13) 
+ + - - - Luminal A 
31 
rev ish enh(1p31p32,1q12q43,8q11q24,10p11p15,22q13),dim(Xp11p22,Xq22q27,1p13p22, 
1p36,8p12p23,10q25q26,11p11p15,11q22q25,13q21q33,14q24q31,15q11q25,16q12q24,17p12p13), 
amp(1p31,1q21q42) 
+ + - - - Luminal A 
32 




- - - - + Basal-like 
33 
rev ish enh(1q21q42,2p13,4q35,5p15,5q13q21,8q11q24,9p21p23,9q22q34,10p12p15,10q21q23,13q12, 
16p12p13,17q12q21,20q11q13),dim(3q11q12,8p21p23,11q22,13q14q21,13q31q34,18p11),amp(8q21q24) 
- - + + - ERBB2 positive 
34 rev ish enh(1q22q42,2p13,2q31,8q13q24,9q34,19p13,21q22),dim(1p36,6q13q16,8p21p22,13q21q33) - - + + - ERBB2 positive 
35 rev ish enh(1q12q42),dim(6p21,11q22q23,16q12q24,17p12p13,17q11q25) + - - + - Luminal A 
36 rev ish enh(1q21q43) + + - - - Luminal A 
37 rev ish enh(17q21q25),dim(8p21) + - + - - Luminal B 
38 
rev ish enh(1p34p36,1q21,9q34,10q26,11q13,15q12q15,15q22q24,17p13,17q11q21,17q25,19p13,19q13, 
20q12q13,22q11q13) 
+ - + - - Luminal B 
39 rev ish enh(1q12q42,17p12q21,19p13q13),dim(6q21q27,16q12q24) + + - - - Luminal A 
40 rev ish enh(11q13),dim(6q13q16,6q22,6q25q27,8p21p22,11q23,13q21) ? ? - ? ? Unclassifiable 
41 rev ish enh(9p22p23,11q13q21),dim(Xp22,8p21p22) - - - + - Basal-like 
42 rev ish enh(9q34,12p13,16p11p13,),dim(3p13p24,10q22q25,16q24,17p13) + + - - - Luminal A 
43 
rev ish enh(1q21q43,8p11p23,8q11q24,16p11p13,17q12q25),dim(7q31q35,14q24q32,16q12q24,17p12p13, 
21q21q22,22q11q13),amp(1q21q41) 
+ + + - - Luminal B 
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44 rev ish enh(1q22q43,3q26,5q31q33),dim(11q24) ? ? - ? ? Unclassifiable 
45 
rev ish enh(1q12q21,1q25q43,4p13p16,4q21q24,4q26,4q31,5p13p15,8p21q24,17q11q25),dim(3p21p25,11p15, 
11q23q25,13q14q34,15q15q25),amp(8q11q22,8q22q24,17q12q21,17q23q24) 
- - + - - ERBB2 positive 
46 
rev ish enh(Xp21p22,1p34,1q12q43,3p22p26,3q21,5p14p15,8q12q24,9p23p24,10p11p15,11p12p15,18q12q22), 
dim(12q24),amp(8q24) 
- - - - + Basal-like 
47  rev ish enh(1q12q43,20p12p13),dim(16q12q24,21q11q22) + + - - - Luminal A 
48 
rev ish enh(1q21q43,5p13p14,7p13p22,7q36,8q13q22,10p12p15,11q13q22,14q12q24,17q21q25,20p13, 
20q11q13),dim(2p23p25,3p13p21,4p13p16,5q13q21,5q33q35,6q21q22,6q25q27,8q24,9p24q34,10q11q25, 
13q12q34,14q31q32,16q24,18q12q23),amp(1q25q41,7p14p21,17q22q24) 
+ + - + - Luminal A 
49 rev ish enh(8p11p21,20q11q13),dim(3p13p24,6q12q27,8p22p23,11q23q25,13q14q33),amp(8p12p21,20q12) + + - - - Luminal A 
50 
rev ish enh(1q21q43,3q12q29,8q11q24,20p11p13,20q11q13),dim(1p13p36,2p25,4p12p15,4q12q35,6q13q22, 
7q22q36,8p12p23,15q15q22,18p11,18q11q23),amp(1q21q43,8q11q24) 
+ + + - - Luminal B 
51 rev ish enh(1q12q43,8p22p23),dim(4p16,9p13p24) + + - - ? Luminal A 
52 rev ish enh(1q21,1q25q41,11q13q21,14q32,15q11q14),dim(Xp11p22,Xq13q27,3p14p24,10q11q24) + + - - - Luminal A 
53 
rev ish enh(1q12q43,5p13p15,5q11q35,8q11q24,12p11p13,12q12q24,14q11q24,16p11p13,17q21q25,20p12p13, 
20q11q13),dim(1p32p36,6q21q23,8p12p23,9p12p21,11q23q24,14q24q32,18p11q22,22q13),amp(1q31,8q23q24,
17q21q24) 
+ + + - - Luminal B 
54 
rev ish enh(1p22p36,1q21q25,1q32q42,2p12,2p22p24,2q11q21,3q21,6p21p25,6q25q27,8q13q24,10p11p15, 
10q11q21,10q25q26,11p11p14,11q14q23,12p13,15q22,18q12q23,19q13,20q11q13,21q22),dim(2q37,5q22q23) 
- - - - + Basal-like 
55 rev ish enh(4q13q35,8p21q24,11p11p15),dim(4p13p16,6p12p24,6q13q27,8p21p23,11q14q25,17p12p13) + + - - - Luminal A 
56 
rev ish enh(1p13p21,1q21,1q25q42,6p21p25,8p11p21,10p12p15,10q22,11p11p14,11q13q22,12q24,14q24, 
16p11p12,16q12,17q12q25),dim(1p22p34,1p36,4p13p16,8p22p23,11q23q25,17p12p13,18q12q21), 
amp(8p12p21,17q21q24) 
+ - + - - Luminal B 
57 
rev ish enh(1q12q24,1q31q42,3q12q13,4q28q35,6p21p22,11q13,12q15q23,17q21q25,18q21q23,20q11q13), 
dim(1p32p36,3p13p21,3q21q25,6q25q27,11p15,11q23q24,12p12p13,13q12q22,16q11q24,17p11q12,19, 
22q11q13),amp(1q21,3q12q13,17q21q24) 
+ - - + - Luminal A 
58 rev ish enh(1q12q42,7p12p21,7q11),dim(1p21p31,7q21q36,16q12q24),amp(7p14p15) + + - - - Luminal A 
59 rev ish enh (1q21q43) - - - + + Basal-like 
60 No alterations + + - - - Luminal A 
61 





+ + + - - Luminal B 
62 rev ish enh(17q11q12),dim(16q12q24) + + + + - Luminal B 
63 
rev ish enh(1p21p32,1q12q22,1q42q43,2p14p16,3q12q29,5p13p15,6p25q21,8p12q24,9p13p21,11p15, 
11q13q23,13q21q34,17q23q25),dim(Xq23q26,1p36,3p21,4p21q13,5q13q32,6q25q27,8p22p23,13q12q13,14q24
q32,15q11q22),amp(8p12,11q14q22) 
- - - + + Basal-like 
64 




- - + + - ERBB2 positive 
65 
rev ish enh(6p12q12,8q13,8q22q24,12p12p13,12q13q24,16p11p13,17,22q11q13),dim(6q13q27,11p11p15, 
11q14q25,13q12q34,14q11q32,16q12q24) 
+ + - + - Luminal A 
Results 
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rev ish enh(1q12q31,1q42,3p13p21,3q21q29,8p11p12,8q22q24,9p21q21,10p13p14,18q21q22),dim(4q31q34, 
5q35,8p22p23) 
- - - + + Basal-like 
67 rev ish enh(8p11p21,8q13q24,10p12p15),dim(8p22p23) + + - - - Luminal A 
68 No alterations + - - + - Luminal A 
69 
rev ish enh(1q32,4q21,8q23q24,11p12p15,11q13q23,12q13q14,17q12q24),dim(Xq21q27,1p13p36,2q21q37, 
9p13p24,9q12q34,11q23q25,16q12q24,22q11q13),amp(11p15,11q13q22) 
+ + - - - Luminal A 
70 
rev ish enh(1p34,1q31q42,2p23p25,3q21q28,5p14,5q14q23,6p22p24,8q11q24,10q24q26,12q14,14q32, 
17q12q24,21q21),dim(1p13p31,1p36,2q12q37,4p13p16,5q31q32,8p21p23,9p21p24,9q21q22,11q14q25,12q24, 
15q15q22,17p11p13,19p13,22q11q13),amp(8q21q23) 
+ + + - - Luminal B 
71 
rev ish enh(1q12q43,22q11q13),dim(8p21p23,8q11q13,9p13p23,9q13q34,11p12p15,13q13q34,16q11q24, 
17p11p13,17q11q25,18p11,18q11q23) 
+ - - - - Luminal A 
72 rev ish enh(1p32p35,1q12q42,3q12q21,8q23q24,17q12q21,19q13),dim(4q31q35,8p12p22,10q25q26) - - + - - ERBB2 positive 
73  rev ish enh(1q21q42,8, 11p11p15,11q13q14,16p12p13),dim(1p13p36,7,11q22q25,16q12q24) + + - - - Luminal A 
74 rev ish enh(1q12q43,3q26q29,9q12q34,12p11p13,17q12q21),dim(4p15p16,10q26,11q24,14q32) - - - + + Basal-like 
75 rev ish enh(8p11p21,16p11p13,20q11q13),dim(11q23) + + - - - Luminal A 
76 




+ + + - - Luminal B 
77 
rev ish enh(Xq26q28,3q12q29,16p13,17q25,20q11q13),dim(1p22q31,3p21p25,8p12p23,9p22p24,11q22q24, 
15q11q15,17p13,18p11q22,22q12q13) 
+ - - + - Luminal A 
78 
rev ish enh(3q11q28,5q13q35,8q11q21,8q23q24,10p11p13,17p12,17q12q25,20q11q13),dim(3p21p26,7p21p22, 
7q32q35,8p21p23,9q22q34,16q12q24) 
+ + + - - Luminal B 
79 rev ish enh(1q12q43),dim(16q12q24) + + - - - Luminal A 
80 No alterations + + - - - Luminal A 
81 rev ish enh(1q12q43,8q12q24,16p11p13,17q12q21,21q21q22),dim(17p13) - + + - - Luminal B 
82 
rev ish enh(1q22q32,1q42,8p21q24,17q21q25,19q13,20,22q13),dim(1p36,2p23,6q21,9p21p22,9q22q33, 
10p11p13,10q11q21,10q23q24,11q22q25,13q12q34,14q24q31,15q11q22,18q12q22,21q21),amp(8p11p21, 
8q23q24) 
? ? + ? ? Unclassifiable 
83 rev ish enh(1q21q42,4q21q24,4q32q34,13q34,15q22q26,17q21q25) + + + - - Luminal B 
84 
rev ish enh(1p13p36,1q21q43,3q12q29,9p13p24,9q21q34,16p11p13,20p11p13,20q11q13),dim(3p21p24, 
4q12q35,6q12q23,7q11q36,17p11p13,17q11q12,17q23q25,22q13),amp(3q21q29) 
+ + - - - Luminal A 
85 
rev ish enh(1p21p32,1q12q42,2p13p25,3q22q29,7p15p21,7q21q22,8q11q21,8q23q24,9p21p23,9q12q21, 
9q31q34,11q13q22,16p12p13,17q21q24,18p11),dim(Xp11p22,Xq12q27,1p36,3p21,4,5p13p15,5q13q34, 
8p12p23,12p12,12q12q24,14q11q24,15q21q22,16q24,17p11p13),amp(8q23) 
- - - - - Basal-like* 
86 
rev ish enh(2p11p12,2q11,3q11q29,4q26q31,8q11q24, 12p11p13,15q22q25,17q21q25),dim(Xp11p22, 
Xq21q28,3p21p24,5q12q35,8p21p23,10p11p15,10q21q26,11q13,11q23,14q12q32,15q11q21,17p13,17q12q21),
amp(8q11q21,8q24,12p12p13) 
- - - - + Basal-like 
87 rev ish enh(1q21q42),dim(6p12p21,6q12q21,6q25q27,16q12q24,22q12q13) + + - - - Luminal A 
Results 
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rev ish enh(3p21p25,3q21q24,3q26q27,4p13p16,4q21q25,4q28q35,5p13p15,5q12q35,8p11p21,8q11q24, 
16q12,17q11q25,20),dim(8p22p23,11p12p15,11q12q25,13q12q34,14q11q32,16q13q24) 
+ + + - - Luminal B 
89 rev ish enh(1q12q42,10q22q23,14q32,17q11q21),dim(8p21) - - - - - Basal-like* 
90 
rev ish enh(1q32,3p25p26,3q29,8q22q24,10p11p15,10q21,10q26,12q13q24,14q11q24,14q32,16p12p13, 
17q12q25,20q13,21q22),dim(1p13,1p22p31,3p13p21,4p12p16,7q11q21,9p13p21,11p11p15,11q21q25,17p13, 
18q12q22),amp(10p12p13) 
+ + + - - Luminal B 
91 rev ish dim(11p11p14,11q22q24,16q12q24) + + - - - Luminal A 
92 
rev ish enh(2p14p16,3q21q29,7p15p22,8q21q24,10q11q21,10q25q26,13q14q21,13q31q34,18p11,20p12), 
dim(8p21p22,11q23q25,18q22) 
- - - + + Basal-like 
93 rev ish enh(1q12q43),dim(6q13,11q23q24,16q11q24,17q21q25) + + - - - Luminal A 
94 
rev ish enh(1q12q43,8p23q24,16p11p13,16q12q24,20p11p12,20q11q13),dim(1p36,2q21,2q31,4p16,4q31q34, 
6q13q23,9q34,15q22q26,22q11q13) 
+ + - - - Luminal A 
95 
rev ish enh(1p13p35,1q12q43,2q33q36,6q25q27,8q21q24,13q34,15q22q26,17q21q25,18q21q23, 
20q12q13),dim(Xp11p22,1p36,3p13p21,6q13q21,7q21q36,8p11p21,11p15,11q21q25,13q12q14,14q24q32, 
16q12q24,17p13,22q11q12),amp(8q22q24) 
+ + - + - Luminal A 
96 
rev ish enh(3q25q29,8p11p12,8q12q24,16p13,20q11q13),dim(Xq12q21,1p22p34,1p36,3p21,4q28,7q21q36, 
8p21p23,9p22p24,11q23q25,16q24,17p12p13,18q21q22) 
+ + - - - Luminal A 
97 rev ish enh(1q21q32,7p13p22,7q11q36,11p15,11q13),dim(1q42q43,6q24,11q23,22q12q13) + + - - - Luminal A 
98 rev ish enh(1q21q42),dim(11q23q25,16q24) + + - - - Luminal A 
99 
rev ish enh(1q21q41,2p14p22,3q26q28,4q12q21,5p13p15,6p21p25,7p13p22,8q22q24,12q14q23,17q21q25, 
18q21q22,20q12q13,21q22),dim(1p36,4q28q35,5q14q21,5q32q34,9p13p23,11p12p15,11q23q24,13q21q33, 
15q22q25,16q11q24,17p13q12,21q21),amp(5p14p15,8q23q24) 
+ - - ? - Luminal A 
100 rev ish enh(1q12q43,8p11q24),dim(8p23),amp(1q21q31) - - - + - Basal-like 
101 rev ish enh(1q21q42,3q12q28,5q23,5q32q35),dim(13q21q33) + + - - - Luminal A 
102 
rev ish enh(1p31p33,1q42,2p12p21,3q22q29,5p13p15,7q22q36,8q12q24,9q21,17q21q24,20p13,21q21q22), 
dim(Xp11p21,Xq12q13,Xq23q25,Xq27,5q33q35,8p21p23,13q12q13,14q24,16q11q23),amp(3q26q27,5p14) 
? ? - ? ? Unclassifiable 
103 rev ish enh(8p12,8q11q24,11q13q22,12q14q24, 20q11q13),dim(6q13q21,6q24q27,14q24q32) + + - - - Luminal A 
104 rev ish enh(8p11p21,8q11q24,12q12q14,16p11p13),dim(11p15) + + + - - Luminal B 
105 
rev ish enh(1q12q43,3q12q13,3q26,5q22q23,6p21p23,8p22p23,8q11q24,12q13q23,14q24,15q21,17q21q25, 
20q11q13,22q11q13),dim(4q27q31,6q13q27,8p12p21,9p13p23,11q13q24,17p13q12,19p13),amp(8p23,8q21q24,
12q14q15,17q22q24) 
+ - - - - Luminal A 
106 rev ish enh(17q11q21) - - + - - ERBB2 positive 
107 
rev ish enh(1q12q43,2p11p25,3q13q29,5p13p15,5q12q21,5q34q35,7p13p22,8q11q24,9q21q22,13q12q34, 
15q22,17q11q25,20q11q13,21q21q22),dim(Xp11p22,Xq13q26,1p13p31,1p36,4p12p16,6q13q27,8p21p23, 
9p13p24,10q26,11q23q25,12p11p13,17p13,18q12q22),amp(17q12q24) 
- - + ? - ERBB2 positive 
108 rev ish enh(8q11q24,16p11q12),dim(8p21p23,12q24,16q24),amp(8q12q24) + + - - - Luminal A 
109 
rev ish enh(1q21,6p12p21,6q21q22,6q25q27,8p11p21,8q21q24,16p13q12,19q13,20p12q13, 
21q22),dim(3p12p14,10p13,11q23,12p13,13q31q33,15q12q14,15q21q22),amp(8p21,8q21q24) 
+ + - - - Luminal A 
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110 rev ish enh(16p11p13),dim(6q22q24,16q12q24,22q11q13) + + - - - Luminal A 
111 
rev ish enh(8p11p21,12q14q24),dim(8p22p23,9p12p23,9q13q34,13q12q33,14q12q21,14q24q32,16p12, 
16q11q24,17p12p13,18p11,18q11q21),amp(8p11p21) 
+ + - - - Luminal A 
112 rev ish enh(7p22q32,13q12,14q11q21,14q24q32),dim(13q14q34,17p12p13,17q12q25),amp(7q11,7q31,13q12) + + - - - Luminal A 
113 rev ish enh(7q32q35,8p21q24,20q11q12,21q21q22),dim(11q23q25,18q21) ? ? - ? ? Unclassifiable 
114 
rev ish enh(1q42q43,7p14p21,12q14q15,19p13),dim(4q25q31,8p21p23,12q24,15q15q26,16q12q24,17p12p13, 
22q12q13),amp(7p15) 
- - - - - Basal-like* 
115 rev ish enh(16p12p13,17q21),dim(1p35p36,3p13p25,4q22q28,6q13q27,16q12q24,17p11p13) + + + ? ? Luminal B 
116 




+ - - + - Luminal A 
117 
rev ish enh(1q21q24,1q42q43,2p22p25,2q11q14,3q22q28,7q36,10p12p15,17q12q21,19q13),dim(4q32q34, 
12q24) 
- - + + + ERBB2 positive 
118 rev ish enh(3q25,8q22,10p11p15,10q21q22) - - - + + Basal-like 
119 rev ish enh(1q21q42,8q22),dim(Xq13q21,8p21p23,11q23q25,15q11q22,18p11) - - + + - ERBB2 positive 
120 rev ish enh(1q31q32) + + - - - Luminal A 
121 rev ish enh(1q21q42,17q12q25) ? ? + ? ? Unclassifiable 
122 
rev ish enh(1q12q43,5p13p15,8q24,16p11p12),dim(1p21p36,2p23,4q21,6q14q21,6q23q27,9q22q33,16q12q23, 
22q12) 
+ + + - - Luminal B 
123 
rev ish enh(Xq13q27,1p12p35,1q12q43,2q22q24,3p12p13,3p21p24,3q12q27,5p14,6p25q16,7p15p21,7q31q36, 
8p12q24,9p13p24,9q34,11q22q23,18q12q22,20q12q13),dim(2q37,5q13q35,8p21p23,12q24,13q14q34, 
14q11q24,14q32,15q11q26,17),amp(1p22p31,1q21q42,8p11q24) 
? ? - ? ? Unclassifiable 
124 rev ish enh(1q21q43),dim(16q12q24,17p12p13) + + - - - Luminal A 
125 rev ish enh(1q22q41,8q22q24,17q12q21),dim(Xq11,8p11p23) - - + + - ERBB2 positive 
126 
rev ish enh(1p32p35,1q21q42,5q13q33,5q35,7p13p15,7q11q32,10p11p14,10q21q23,10q26,11q13q14, 
12p11p13,12q13q24,14q11q24,20p12,20q11q13),dim(Xq23q26,3p13p24,4q28q35,6p12p21,8p11p23,13q12q34,
15q11q14),amp(14q12q24) 
? ? - ? ? Unclassifiable 
127 rev ish enh(4q12q21,16q11q24,18p11) + + - - - Luminal A 
128 
rev ish enh(1q12q42,5p13p15,5q12q35,8p21,8q24,14q24q31,16p11p13,20p11p13,20q11q13),dim(11p12p14, 
11q13q23) 
+ + + - - Luminal B 
129 
rev ish enh(1q12q43,16p11p13,20p11p12,20q11q13),dim(1p13p36,3p22p24,11p11p15,11q13q25, 
12p12,13q12q34,16q12q24) 
+ + - - - Luminal Ale 
130 




- - - + - Basal-like 
131 rev ish enh(1q121q43,7p15q22,10p11,10p13p15,10q22q23),dim(10q25,13q22q33) + + - - - Luminal A 
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rev ish enh(7p12p22,7q11q21,7q31q36,16p11p13,20p11p13,20q11q13),dim(1p34p35,3p21p24,11q22q24, 
16q12q24,17p11p13,21q11q22,22q11q12),amp(7q32) 
+ + - ? - Luminal A 
133 rev ish enh(1q12q43,5p13p15,5q13q35,16p11p13,17q21q25,18q12q22),dim(16q11q24),amp(1q21q32) ? ? + ? ? Unclassifiable 
134 




+ + - - - Luminal A 
135 
rev ish enh(1q12q43,8q23q24,12q12q13,16p11p13,17q21q25),dim(9p21,9q12q34,18q21), 
amp(8q24) 
+ + + - - Luminal B 
136 
rev ish enh(1q21q43,2p13,2p23p24,5p15,5q13q35,8p11p21,8q21q22,12p12p13,12q14q24,15q22,16p11p13, 
16q12q23,17q23q25,20q11q13),dim(6p21,6q12q27, 11q23q25,13q12q14,13q31q33,14q24q31),amp(8p12p21) 
+ + + + + Luminal B 
137 
rev ish enh(1p13p32,1q21q43,2p16q14,2q33q37,3q25q29,5p13p15,6p12p25,6q24,7p12p14,8q22q24,9p12p13, 
9p22p24,11p12p14,11q13q21,13q13q14,13q22q34,16p11p13,18p11,21q21),dim(1p36,4p16,4q21q25,4q31q35, 
5q13q33,8p21p23),amp(1q31,9p23p24,13q34) 
? ? - ? - Unclassifiable 
138 
rev ish enh(1q12q43,8q21q22,19q13,21q22),dim(3p14p21,4p13p16,4q31q35,6q12q27,9p12p24,10q23q26, 
11q22q25,13q12q14,14q11q12,17p12p13,22q11q13) 
+ - - + - Luminal A 
139 rev ish enh(8q13q24,11p12p15,17q12q25),dim(13q31q34) + + + - - Luminal B 
140 rev ish enh(20q11q13) + - + + - Luminal B 
141 rev ish enh(11),dim(9p22p24) + + - - - Luminal A 
Legend: 
a
RE, PgR, CKs 5/6 and 14 protein expression status were evaluated by immunohistochemistry. 
Cases were considered positive (+) or negative (-) if 10% or <10% of cells were positive, respectively. 
b
ERBB2 status was evaluated by FISH or CGH. The cases scored as positive (+) presented ratios ERRB2 
gene signals to chromosome 17 centromere signals 2.2 on average for at least 60 tumor cells and by CGH 
whenever the 99% CI of the fluorescence ratio was above 1.5 in a regional gain involving 17q12 or the entire 
17q arm; negative cases (-) presented ratios ERRB2 gene signals to chromosome 17 centromere signals 1.8 - 
2.2 on average for at least 100 tumor cells or <1.8 for at least 60 cells and by CGH whenever the 99% CI of 
the fluorescence ratio was inferior to 1.5 in 17q12. 
c
Molecular classification was based on Tang et al (25). ?: 
Not analyzable. *Triple-negative cases were considered as together with basal-like group for statistical 
analysis.  
2. OVERALL PATTERN OF GENOMIC CHANGES BY CGH 
One hundred and forty one breast cancer cases were analyzed by CGH. The 
number of genomic imbalances ranged from 0 to 49 per case, with a median of 9.0 
(Table 7).  
The number of copy number gains varied from 0 to 26 (median: 5.0) and losses 
from 0 to 21 (median: 4.0). The chromosome arms from which material was most 
frequently gained were 1q (the most commonly gained bands were 1q21 and 
1q32; 56.7%), 8q (45.8% at 8q24), 20q (33.1% at 20q13), 17q (29.6% at 17q21) 
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and 16p (28.9% at 16p12). On the other hand, the arms most often displaying loss 
were 16q (38.0% at 16q24), 11q (35.2% at 11q23), 8p (33.1% at 8p22), 17p 
(29.6% at 17p13) and 13q (20.4% at 13q31~q33). Fifty five cases (39.0%) showed 
amplifications of one to five discrete chromosomal regions, most frequently at 8q 
(18 cases), 1q and 17q (eight and seven cases, respectively), 7p and 10p (four 
and three cases, respectively) and 20q (two cases). 
The chromosomal bands where ETS genes are located displayed the following 
chromosomal imbalances indicated in Table 8. 
TABLE 8: Correlation of CGH imbalances at ETS gene loci in 141 breast carcinomas. 
GENE LOCUS GAIN (%) LOSS (%) 
ETV3 1q21~q23 56.3-53.5 0 
ELF3 1q32.2 56.3 0 
ELK4 1q32 56.3 0 
ETV5 3q28 16.2 0 
ETV1 7p21.3 12 1.4 
ETS1 11q23.3 3.5 35.2 
FLI1 11q24.1~q24.3 2.1 31 
ETV4 17q21 29.6 6.3 
ETS2 21q22.2 11.3 4.9 
ERG 21q22.3 11.3 4.9 
 
3. 1q ETS COPY NUMBER GAINS BY FISH 
As 1q21 and 1q32 were the two chromosome bands with most frequent genomic 
gains by CGH (both loci gained in 71 cases and additional 18 cases with copy 
number gain in one of the two loci, 9 cases each), and were the only chromosomal 
imbalances associated with differential expression of the ETS genes harbored in 
these chromosomal regions, from here our work was focused on only in the three 
ETS genes localized in 1q. We evaluated the copy number of the genes ETV3 
(located in 1q21~23) and ELF3 and ELK4 (both in 1q32) by FISH with specific 
BAC clones. Whereas breast carcinomas with no 1q copy number changes by 
CGH were also normal by FISH, this analysis showed copy number gains of the 






FIGURE 6: A) CGH profile of chromosome 1 
showing two discrete copy number gains 
including 1q21~q23 (ETV3 locus) and 1q32 
(ELF3 and ELK4 loci) together with a large 
1p terminal deletion. B) CGH profile of 
chromosome 1 showing two discrete copy 
number gains including 1q21~q23 (ETV3 
locus) and 1q32 (ELF3 and ELK4 loci) 
together with a small interstitial 1p deletion. 
C) Interphase FISH analysis demonstrating 
copy number gain of ETV3 (green) and ELF3 
(red). D) Interphase FISH analysis of another 
breast carcinoma demonstrating copy 
number gain of ETV3 (green) and ELK4 
(red). 
4. ETS GENE EXPRESSION  
From the 141 breast cancer cases evaluated by CGH, 114 cases were also 
analyzable by qRT-PCR. The expression of ETV3 was higher in breast 
carcinomas with copy number gain of 1q21~q23 than in those without (Mann 
Whitney test; p<0.01), whereas the expression of ELF3 was higher in breast 
carcinomas with copy number gain of 1q32 than in those without (Mann Whitney 
test; p<0.01) (Figure 7). No such association was found for ELK4 expression and 
1q32 imbalances, nor for the remaining ETS studied.  
 
FIGURE 7: Box-plot graph 
showing ELF3 expression 
according to the presence or 
absence of 1q32 copy number 
gain (Mann Whitney test). 
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5. EXPRESSION OF POTENTIAL ETS TARGET GENES 
MYC expression was not associated with copy number increase at 8q24, but it 
was correlated with the expression of ETV3 and ELK4 genes (rs=0.255, p<0.01, 
for ETV3; rs=0.639, p<0.01, for ELK4) (Figure 8). CRISP3 expression was not 
associated with copy number increase at 6p23 and it was only correlated with 
ELK4 expression (rs=0.474, p<0.01). 
 
FIGURE 8: Non-parametric correlation between ELK4 and MYC mRNA expression (Spearman 
test). 
6. CLINICO-PATHOLOGICAL CORRELATIONS 
Breast carcinomas were classified according to the four molecular groups defined 
by Perou et al (20) and then by Tang et al (25), the latter using 
immunohistochemical markers in parallel with cDNA microarray analyses. Breast 
tumor phenotype was classified in four subgroups: luminal A (ER and/or PR 
positive and ERBB2 negative); luminal B (ER and/or PgR positive and ERBB2 
positive); basal-like (ER, PgR and ERBB2 negative; and CKs 5/6 and/or 14 
positive); and ERBB2 positive (ER and PgR negative and ERBB2 positive). Using 
these criteria, 71 cases were classified as luminal A (50.4%), 30 as luminal B 
(21.3%), 11 as ERBB2 positive (7.8%) and 15 as basal-like (13.4%) (Table 7), 
which is in agreement with other published studies (26). Four cases were triple-
negative and did not express CKs 5/6 or 14, but were considered together with 
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basal-like tumors for statistical analyses. Ten cases were unclassifiable. The 
basal-like molecular subtype presented the worst prognosis regarding disease-
specific survival with death by disease as the end point, showing a statistically 
significant difference when compared with luminal B (p=0.031) and a tendency 
when compared with luminal A (p=0.096) (95% CI). The comparison of prognosis 
between the other molecular subtypes showed no significant difference, and no 
association between particular breast cancer molecular subtypes and the 
presence of 1q copy number gain or the ETV3, ELF3 or ELK4 expression levels 
could be observed. In the only group with a number of cases sufficient to allow the 
comparison (luminal A), no prognostic value was found for 1q copy number status 
or ELF3 expression (Figure 9). 
FIGURE 9: A) Comparison of disease-specific survival for 1q copy number status in luminal A 
breast carcinomas, as compared to the basal molecular subtype showing the worst prognosis. B) 
Comparison of disease-specific survival for ELF3 expression above and below the mean in luminal 
A breast carcinomas, as compared to the basal molecular subtype showing the worst prognosis. 



















































1. 1q COPY NUMBER CHANGES AND 1q ETS EXPRESSION 
Copy number gain of chromosome 1q is the most common genomic imbalance in 
breast carcinomas (45, 80), as confirmed by our findings in the series we here 
present. The target genes of the recurrent 1q gain have so far remained elusive 
and, given the role of the ETS family of transcription factors in several human 
malignancies, we asked whether the three ETS genes located in this chromosomal 
arm could be relevant targets in this subset of breast carcinomas. In fact, we here 
show that the 1q chromosome bands showing the highest frequency of copy 
number gains (56.7%) are exactly those harboring the three ETS loci, namely 
1q21 (where ETV3 is located) and 1q32 (where both ELF3 and ELK4 are located). 
Copy number gains of ELF3, ETV3 and ELK4 were subsequently confirmed by 
FISH with locus specific probes. Furthermore, we here show for the first time that 
there is an association between ELF3 and ETV3 copy number gain and 
overexpression of these two genes in breast carcinomas, irrespectively of the 
breast cancer molecular subtypes.  
The same association of copy number changes and gene expression was not 
evident for the remaining ETS genes included in the study. In face of these results, 
our work focused on the 1q ETS genes and their possible role in breast cancer. 
2. THE ROLE OF ELF3 IN BREAST CARCINOGENESIS 
ELF3, along with ELF5 and EHF, belongs to the clade Epithelium-Specific ETS 
(ESE) factor (57), a group of epithelium-restricted transcription factors with 
important function in epithelial cell differentiation (81, 82). In situ expression 
analysis performed in human mammary gland showed that ELF3 is expressed 
specifically in the epithelial cells of the ductules and lobular structures (73). 
Additionally, ELF3 mRNA increased levels were detected in murine models within 
mammary gland epithelium during pregnancy and early lactation (73). Both 
evidences suggest that ELF3 may be involved in controlling processes related with 
cellular proliferation and differentiation, as the mammary gland undergoes 
extensive epithelial proliferation along with subsequent differentiation and milk 
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protein synthesis during pregnancy and lactation (83). This protein can also be 
involved in apoptosis. Studies in murines revealed that its transcript is also 
elevated during gland mammary involutions phases (83), which is intrinsically 
associated with apoptosis and remodelling pathways. Endogenous ELF3 is 
expressed in the cytoplasm and/or in the nucleus at very low levels, both in normal 
and in breast cancer tissues, as well as in benign non transformed mammary 
epithelial cells and in breast cell lines (73, 82, 84). Nevertheless, compiling 
evidence indicates that aberrant ELF3 expression may alter normal breast 
remodelling processes and result in tumorigenesis (73, 82, 83, 85-87).  
It was previously alleged that many ETS factors exert their transforming effects in 
mammary epithelial cells only through nuclear transcription activity (73), but, as 
mentioned above, ELF3 protein is also localized within the cytoplasm in human 
breast cancer cells. The initiation of transformation of benign MCF-12A cells by 
stable expression of ELF3 is mediated by its SAR domain (serine and aspartic 
acid-rich domain), which acts in the cytoplasm via an unknown non-nuclear and 
non-transcriptional mechanism (82). On the other hand, the nuclear localization of 
ELF3 protein maintains the transformed mammary epithelial phenotype of fully 
transformed mammary epithelial cells via regulation of cellular proliferation, which 
is coordinately regulated by PAK-1 phosphorilation (84, 88). So, according the 
cellular localization, ELF3 protein has different roles in oncogenesis. Taking in 
account all these data, we can postulate that ELF3 initiates cellular transformation 
via a cytoplasmatic and PAK-1-dependent mechanism, but once fully transformed 
the cells require the nuclear transcription properties of ELF3 to sustain the 
transformed phenotype (84). 
Several lines of evidence indicate that a forward autocrine regulatory loop may 
exist between ELF3 and growth factors, namely ERBB2, and that such a 
regulatory loop contributes to the regulation of cell proliferation, and ultimately to 
cell transformation by ELF3 (73, 84, 89-91). Regarding ELF3/ERBB2 loop, studies 
demonstrated that ELF3 transcription is regulated by ERBB2 receptor signaling in 
epithelial breast cancer cells, where expression of ERBB2 up-regulates ELF3 
promoter activity, while inhibition of ERBB2 or its downstream signaling pathways 
decrease both ELF3 promoter activity and endogenous ELF3 protein level. It is 
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thus likely that the ELF3 promoter is a potential transcriptional target of the ERBB2 
protein. Additionally, ELF3 expression seems to be a downstream mediator of 
ERBB2 signaling and that ERBB2 induce ELF3 gene expression in the context of 
breast tumorigenesis. Moreover, it has also been reported that ELF3 and ERRB2 
can cooperate to confer an invasive phenotype in human mammary epithelial cells 
(73, 87).  
Other studies described an additional role to ELF3: it was demonstrated that ELF3 
can contribute to the control of TGF-β signaling pathway in human breast cancer 
cells, by inducing the TGF-β RII expression. Blocking ELF3 activity, the authors 
demonstrated a significant reduction in resistance to the growth inhibitory effects 
of TGF-β, which may contribute to breast carcinogenesis (92).  
The seminal works performed by Gallang et al (67) and He et al (69) tried for the 
first time to evaluate ETS expression in breast cancer cell lines and in tumor 
specimens, respectively. They found increased ELF3 mRNA levels in breast 
cancer cell lines and in tumor breast samples comparatively to normal breast cells. 
Although the paucity of breast cancer cases analyzed could bias the results (69), 
our data support their findings. Additionally, using FISH data, we found that the 
genetic mechanism promoting ELF3 overexpression is associated with gene copy 
number gain/amplification.  
3. THE ROLE OF ETV3 IN BREAST CARCINOGENESIS 
The role of ETV3 in breast carcinogenesis is not as well established as for ELF3. 
ETV3 is a member of the ETS-domain family of transcription factors. In 
physiological normal conditions it has been associated with the regulation of 
transcriptome elements of the osteoblasts (93) and in controlling the processes of 
proliferation and differentiation in macrophages (94). According to some evidence, 
the ETV3 protein is localized in the nucleus in transformed cells (95). It functions 
as a transcriptional repressor dependent on a C-terminal active repressor domain, 
blocking mitogenic responses mediated by positively acting ETS factors, such as 
ETS2. ETV3 binds to and represses ETS1/2 target genes, including c-myc, c-myb 
and cdc-2 (96). The repressor function of ETV3 is retained even in the presence of 
Ras/MAPK signaling, enabling ETV3 to dominantly inhibit growth factor-dependent 
proliferation (96).  
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Other studies also demonstrated that the expression of ETV3 in macrophages can 
be activated in response to RAS pathway and positively regulated by CREB-
1/CREM-1, which binds to a conserved GGAA sequence found in ETV3 (97). This 
core sequence represents a binding motif for members of the ETS-domain family 
of transcription factors, which raises the possibility that ETV3 may have the 
capability of transcription auto-regulation (97). In line with these results, after 
screening the substrates of ERK2, a MAPK protein, it was found that ETV3 was an 
ERK2 target in a fibroblast cell line (3T3-L1) (95). ETV3 was extensively 
phosphorilated by ERK2, which abrogated its capacity to bind to target genes and 
repress them. After searching for ETV3 binding sites throughout the genome, 
ETV3 target genes such as ETV3 itself and DDX20 were found. The ETV3 
repressive antiproliferative function depends on the direct interaction with DDX20, 
a DEAD-box containing RNA helicase protein (94). This provides a negative 
feedback control mechanism, which along with constitutive instability may serve to 
accurately regulate ETV3 loads (95). Additionally, phosphorilation by ERK2 
reduces the repression induced by ETV3, permitting the activation of cell cycle 
control genes, such as MYC, components of the NF-kB pathway and genes 
demanded for mRNA processing and translation (95). Once ERK2 activity ceases, 
neotranslated ETV3 can quickly repress its target genes, which results in a 
transitory rupture of transcriptional activity after ERK activation (95).  
The ETV3 mRNA transcript levels between tumor and non-tumorigenic 
immortalized breast cell lines were described as similar (67, 69). A probable 
explanation for this negative results could be the scarce number of tumor samples 
analyzed (69), and/or the short semi-life of ETV3 protein (about 2 hours), in 
conjunction with its auto-regulation capacity (95). The last hypothesis could 
hamper protein but also transcript detection if ETV3 in those few studied samples 
was not phosphorilated, and consequently was auto-repressively active. To the 
best of our knowledge, this is the first study that describes an association between 
1q21~q23 copy number gain, both by CGH and by FISH with specific probes, and 
ETV3 transcript overexpression in breast cancers. However, phosphorylation of 
ETV3 by ERK2, involved in MAPK signaling, abrogates its capacity to bind and 
repress target genes (95). It is therefore possible that overexpression of ETV3 is 
an innocent bystander of 1q gain in breast carcinogenesis and that its potential 
Discussion 
91 
effect as a negative mitogenic regulator is contra-balanced by other oncogenic 
mutations that activate MAPK signaling in breast cancer.  
4. THE ROLE OF ELK4 IN BREAST CARCINOGENESIS 
We also investigated the expression of the third 1q ETS gene, ELK4. It codifies a 
transcription factor that belongs to the TCF (Ternary Complex Factor) family, 
which in vertebrates link transcription to MAPK signaling, in partnership with serum 
response factors (SRF), establishing a ternary complex on the c-Fos promoter 
(98). Previous studies showed that in breast cell lines the levels of mRNA ELK4 
were stable between normal and tumor cells (67) and that ELK4 mRNA was not 
detectable in breast cancer samples (69), which was justified with the non-
confirmed theory of lineage-specific expression of certain ETS genes. 
The expression of ELK4 was not associated with copy number changes at its 
locus. This result is in agreement with integrative analysis of DNA copy number 
and mRNA expression data performed in several biological models, which show 
that gene copy number changes do not necessarily result in expression alterations 
(99-101). In prostate cancer ELK4 overexpression may occur without an 
underlying genetic alteration of this gene, resulting instead from a transcriptional 
read-through mechanism favored by the presence of a nearby androgen 
responsive gene (SLC45A3) located upstream of ELK4 (102, 103). 
5. MYC AS A TARGET GENE OF 1q ETS TRANSCRIPTION FACTORS 
Another goal of this work was to uncover target genes affected by altered 
expression of ETS transcription factors. Among the possible target genes studied, 
we found a correlation between MYC and ETV3 and ELK4 transcript levels.  
MYC locus is 8q24.21 and as most tumors have numerous alterations in signaling 
cascades, MYC is likely to be deregulated by some mechanism in the majority of 
cancers (75). The proportion of breast cancers presenting MYC gene amplification 
(about 15%) is lower than those showing MYC mRNA (from 22 to 35%) or protein 
(approximately 45%) overexpression (37, 74). This fact can be explained by MYC 
being coordinated by multiple signals that regulate its promoter activity, 
transcriptional elongation and translation, as well as by post-transcriptional 
modifications (75). The fact that MYC expression level was not correlated with 8q 
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copy number gain, along with some of the evidence already described above, 
make us postulate that ETV3 and ELK4 are involved in MYC transcriptional 
regulation. 
MYC is a direct ETV3 target gene. When MYC expression is deregulated, ETV3 
exerts its suppressor effects in an attempt to directly repress it. As MYC mRNA 
levels augment, ETV3 mRNA loads also increase in order to be translated and 
repress MYC. On the other hand, since MYC can be positively regulated by c-Fos 
(75, 104), which in turn is activated by ELK4 (105-107), we believe that ELK4 
overexpression is relevant for breast carcinogenesis by indirectly upregulating 
MYC. 
6. CRISP3 AS A TARGET GENE OF 1q ETS TRANSCRIPTION FACTORS 
Noteworthy is also the correlation observed between ELK4 and CRISP3 
expression. CRISP3 belongs to the cysteine-rich secretory protein family, a highly 
conserved protein family among vertebrates (108). In mammals it comprises 
several members predominantly expressed in salivary glands and in male 
reproductive tract, most of which under strong androgen regulation. They were 
originally described in rats and it has been demonstrated that rat sperm-coating 
protein AEG (Crisp1 alias), which is abundantly expressed in the epididymis under 
strong androgen control, is involved in the rats’ spermatogenesis process, post-
testicular sperm maturation and capacitation event (108). Soon afterwards, 
screening of epididymal and salivary gland cDNA libraries allowed the isolation 
and characterization of CRISP1 mouse homolog and CRISP2 protein, two proteins 
that are strictly androgen-regulated. Additionally, CRISP3 mRNA, which presents 
77% of homology with CRISP1, was also identified in mouse salivary gland as 
being an androgen dependent transcript (108). 
Human CRISP3 is a 28kDa (contains 245 aminoacids), extracellular matrix 
protein, detected in several tissues, with predominance in the exocrine tissues, as 
salivary gland, pancreas and prostate, and in less abundance in epididymis, ovary, 
thymus and colon (109-111). CRISP3 gene locus is at 6p12.3, where the CRISP1 
and CRISP2 genes are also localized. The CRISP3 protein is secreted in saliva, 
sweat, seminal plasma and is also a circulating plasma protein and it can be 
stored intracellularly in specific compartments and granules or in association with 
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membrane proteins in glycosyilated states (110, 111). Although the specific 
function is currently unknown, studies of sequence homology between CRISP3 
and pathogenesis-associated proteins in plants, cellular localization and 
expression profile in thymus and neutrophils, which are rich in matrix degradation 
enzymes, resulted in a proposal of immune response related function (112). This 
feature can be associated with proteolysis and cellular matrix remodeling events, 
which in turn, when deregulated, may be associated with carcinogenesis. 
Several studies revealed mRNA CRISP3 overexpression in prostate cancer 
samples (72, 113-115), indicating a possible role in prostate cancer progression. 
Taking into account the results published in public databases of the transcriptome, 
CRISP3 is also expressed in breast tissues but without a significant difference 
between normal and tumor samples. 
ELK4 is a nuclear transcription factor androgen respondent ETS (116). Sixty to 
85% of breast cancers express androgen receptors and even the tumors 
molecularly classified as hormone negative, express androgen receptor, namely 
some triple negative tumors (117, 118). However, the role of androgen receptors 
in breast cancers is still uncertain (117-119).  
After performing in silico studies of CRISP3 as a possible target gene for ETS 
factors, we did not find robust evidence indicating that CRISP3 is an ELK4 target 
gene. Taking this into consideration, we therefore postulate that the observed 
correlation between ELK4 and CRISP3 mRNA expression is mediated by the 
presence of androgen response elements in their promoters, resulting in a 
coordinated but independent expression of these two genes. 
7. CLINICO-PATHOLOGICAL ASSOCIATIONS 
The study did not find an association between particular breast cancer molecular 
subtypes and the presence of 1q copy number gain or the ETV3 and ELF3 
expression levels. Furthermore, we could not find a prognostic value for 1q copy 
number status, nor for ELF3 expression, which is probably the most important 





In summary, we here show for the first time that the most common genomic copy 
number gains in breast cancer, 1q21 and 1q32, are associated with 
overexpression of the ETS transcription factors ETV3 and ELF3 (but not ELK4) at 
these loci irrespective of molecular subtypes. Among the three 1q ETS genes, 
ELF3 is the most likely target of the 1q copy number increase with a relevant role 
in breast carcinogenesis. Additionally, we show that there is a correlation between 
the expression of the oncogene MYC, irrespectively of copy number gain at its loci 
in 8q24, and the expression of both the transcriptional repressor ETV3 and the 
androgen respondent ELK4, a relationship that is worth to explore hereafter. 
FUTURE STUDIES 
Testing the phenotypic impact after the induction in normal tissue/cells or 
repressing in cancer cells the 1q ETS genes would be an interesting approach to 
address their role in breast carcinogenesis. Moreover, to evaluate if target genes 
of ETV3, ELF3 and ELK4 genes are direct or indirect, we should perform ChIP 
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